<SEC-DOCUMENT>0001140361-23-026687.txt : 20230525
<SEC-HEADER>0001140361-23-026687.hdr.sgml : 20230525
<ACCEPTANCE-DATETIME>20230525172626
ACCESSION NUMBER:		0001140361-23-026687
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20230523
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230525
DATE AS OF CHANGE:		20230525

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			U S PHYSICAL THERAPY INC /NV
		CENTRAL INDEX KEY:			0000885978
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HEALTH SERVICES [8000]
		IRS NUMBER:				760364866
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11151
		FILM NUMBER:		23962118

	BUSINESS ADDRESS:	
		STREET 1:		1300 WEST SAM HOUSTON PARKWAY
		STREET 2:		SUITE 300
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77043
		BUSINESS PHONE:		7132977000

	MAIL ADDRESS:	
		STREET 1:		1300 WEST SAM HOUSTON PARKWAY
		STREET 2:		SUITE 300
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77043
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ny20009213x3_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:usph="http://usph.com/20230523" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_c768c2a33e3d4d99b95f597f69bb1f22" contextRef="c20230523to20230523" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_871c3b84f2b44552ae5f2b5e2debfb99" contextRef="c20230523to20230523">U S PHYSICAL THERAPY INC /NV</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_4da354432837412cb84061ac0529e710" contextRef="c20230523to20230523">0000885978</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="usph-20230523.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20230523to20230523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-23</xbrli:startDate><xbrli:endDate>2023-05-23</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold;">
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
<div>UNITED STATES</div>
</div>

  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

  <div><br />
  </div>

  <div>
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_0331098722944fc6b7ab8f11305ee6d6" contextRef="c20230523to20230523">8-K</ix:nonNumeric></div>

  <div>
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

  <div><br />
  </div>

  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">CURRENT REPORT</div>

  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</div>

  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_8ff39f9340194391a0afc3c46184ce1d" contextRef="c20230523to20230523" format="ixt:date-monthname-day-year-en">May 23, 2023</ix:nonNumeric></div>

  <div><br />
  </div>

  <div>
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;"><span style="-sec-ix-hidden:Fact_871c3b84f2b44552ae5f2b5e2debfb99">U.S. Physical Therapy, Inc.</span><br />
  </div>

  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>

  <div>
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

  <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span><br />
  </div>

  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_4cea211ecd234c1a91f72b1a4a0871ea" contextRef="c20230523to20230523" format="ixt-sec:stateprovnameen">Nevada</ix:nonNumeric><br />
          </div>
        </td>

    <td style="width: 34%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_a48b847f433140caae3b5561eb35d24a" contextRef="c20230523to20230523">1-11151</ix:nonNumeric><br />
          </div>
        </td>

    <td style="width: 32.66%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_f795340000b44e51aa010c68ece6e5d0" contextRef="c20230523to20230523">76-0364866</ix:nonNumeric><br />
          </div>
        </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(State or other jurisdiction</div>
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">of incorporation)</div>
        </td>

    <td style="width: 34%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Commission</div>
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">File Number)</div>
        </td>

    <td style="width: 32.66%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(I.R.S. Employer</div>
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Identification No.)</div>
        </td>

  </tr>


</table>
  <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span><br />
  </div>

  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_a6c72eb342404845bb834c3b41625d8c" contextRef="c20230523to20230523">1300 West Sam Houston Parkway South</ix:nonNumeric>,</div>
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_adb5969ec3d14bb1b18cf6a654955ad0" contextRef="c20230523to20230523">Suite 300</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_157c26c8257d402abe3d3f84f7ed6568" contextRef="c20230523to20230523">Houston</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_b0c564a36a3a415090ca77fe71b730bf" contextRef="c20230523to20230523" format="ixt-sec:stateprovnameen">Texas</ix:nonNumeric></div>
        </td>

    <td style="width: 50%; vertical-align: bottom;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_390fb8790fb5430aa8e3ba12ca2aa90a" contextRef="c20230523to20230523">77042</ix:nonNumeric><br />
          </div>
        </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Address of principal executive offices)</div>
        </td>

    <td style="width: 50%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Zip Code)</div>
        </td>

  </tr>


</table>
  <div><br />
  </div>

  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_6503c7ae09f84de8be58cd7c02cf9dd2" contextRef="c20230523to20230523">713</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_91c44c3ced984896b6d7f6633e4f02c2" contextRef="c20230523to20230523">297-7000</ix:nonNumeric></div>

  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Registrant&#8217;s telephone number, including area code)</div>

  <div><br />
  </div>

  <div><br />
  </div>

  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Former name or former address, if changed since last report)</div>

  <div><br />
  </div>

  <div>
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

  <div><br />
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33.33%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title of Class</div>
        </td>

    <td style="width: 33.33%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trading Symbol(s)</div>
        </td>

    <td style="width: 33.33%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name of each exchange of which registered</div>
        </td>

  </tr>

  <tr>

    <td style="width: 33.33%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_dac1bd7f401d4b45acd66ca1167efb49" contextRef="c20230523to20230523">Common stock, $0.01 par value</ix:nonNumeric><br />
          </div>
        </td>

    <td style="width: 33.33%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_e6c6a7f4e6154cb8892918b952fa2633" contextRef="c20230523to20230523">USPH</ix:nonNumeric><br />
          </div>
        </td>

    <td style="width: 33.33%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_a82349740eb44d61a74ad7af7c537c0b" contextRef="c20230523to20230523" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric><br />
          </div>
        </td>

  </tr>


</table>
  <div><br />
  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
    provisions (see General Instruction A.2. below):</div>

  <div><br />
  </div>

  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 2%; vertical-align: top;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_09c517c007ec429bb3774ed8efaef097" contextRef="c20230523to20230523" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
        </td>

    <td style="width: 98%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
        </td>

  </tr>


</table>
  <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span><br />
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 2%; vertical-align: top;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_537db99832cd43299b44b8021b7ed653" contextRef="c20230523to20230523" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
        </td>

    <td style="width: 98%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
        </td>

  </tr>


</table>
  <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span><br />
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 2%; vertical-align: top;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_ac262149b87f49d2920f8a932c4b754b" contextRef="c20230523to20230523" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
        </td>

    <td style="width: 98%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
        </td>

  </tr>


</table>
  <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span><br />
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 2%; vertical-align: top;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_5d3f45d64e4948c5864ee065c007dcb4" contextRef="c20230523to20230523" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
        </td>

    <td style="width: 98%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          <div>&#160;</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or
            Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2). Emerging growth company&#160; <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_81d73f1718034b8f891540cd76741cae" contextRef="c20230523to20230523" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>
          <div>&#160;</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
            or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>
        </td>

  </tr>


</table>
  <div>
    <div>
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

  </div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

  </div>

  <div><br />
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 9.85%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 1.01</div>
        </td>

    <td style="width: 90.15%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Entry into a Material Definitive Agreement.</div>
        </td>

  </tr>


</table>
  <div><br />
  </div>

  <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On May 24, 2023, U.S. Physical Therapy, Inc. (the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8220;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic;">Company</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8221;</span>) entered into an underwriting agreement
    (the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8220;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic;">Underwriting Agreement</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8221;</span>) with BofA Securities, Inc. and J.P. Morgan Securities LLC, as representatives (the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8220;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic;">Representatives</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8221;</span>) of the several underwriters
    named therein (the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8220;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic;">Underwriters</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8221;</span>), to issue and sell 1,666,667<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span>shares of common stock, par value
    $0.01 per share (the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8220;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic;">Common Stock</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8221;</span>), to the Underwriters at a price of $85.50 per share in connection with an underwritten public offering (the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8220;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic;">Offering</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8221;</span>)
    pursuant to the Company<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8217;</span>s shelf registration statement on Form S-3 (Registration No. 333-272147), filed with the Securities and Exchange Commission (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic;">Commission</span>&#8221;) and automatically effective on May 23, 2023 at an Offering price of $90.00 per share. The Company expects the net
    proceeds from the Offering to be approximately $142.3 million, after deducting estimated fees and expenses. The Company has also granted the Underwriters a 30-day option to purchase up to an additional 250,000 shares of Common Stock. The Offering is
    expected to close on May 30, 2023, subject to customary closing conditions. The Company intends to use the net proceeds of this Offering for repayment of a portion of its indebtedness outstanding under its revolving credit facility, and for general
    corporate purposes, including future acquisitions and other capital expenditures, as well as funding working capital and paying dividends.</div>

  <div><br />
  </div>

  <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Underwriting Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing,
    obligations of the parties and termination provisions. Additionally, the Company has agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the Underwriters may be
    required to make because of any of those liabilities. Furthermore, the Company has agreed with the Underwriters not to offer or sell any shares of its Common Stock (or securities convertible into or exchangeable for Common Stock), for a period of 90
    days after the date of the Underwriting Agreement without the prior written consent of the Representatives.</div>

  <div><br />
  </div>

  <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The foregoing description of the Underwriting Agreement is qualified in its entirety by reference to such Underwriting Agreement, a copy of
    which is filed herewith as Exhibit 1.1 and is incorporated herein by reference. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit. A copy of the legal
    opinion of Woodburn and Wedge relating to the validity of the shares issued and sold in the Offering is filed herewith as Exhibit 5.1.</div>

  <div><br />
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 9.85%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 7.01</div>
        </td>

    <td style="width: 90.15%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Regulation FD Disclosure.</div>
        </td>

  </tr>


</table>
  <div><br />
  </div>

  <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On May 23, 2023, the Company issued a press release announcing the Offering. A copy of the press release is filed as Exhibit 99.1 to this
    Current Report on Form 8-K, and is incorporated herein by reference.</div>

  <div><br />
  </div>

  <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On May 24, 2023, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is filed as Exhibit
    99.2 to this Current Report on Form 8-K, and is incorporated herein by reference.</div>

  <div><br />
  </div>

  <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information in this Item 7.01 (including the exhibits) shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities
    Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act of 1933, as amended or the Exchange Act.</div>

  <div><br />
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 9.85%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9.01</div>
        </td>

    <td style="width: 90.15%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Financial Statements and Exhibits.</div>
        </td>

  </tr>


</table>
  <div><br />
  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d) Exhibits.</div>

  <div><br />
  </div>

  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 9%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
          <div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit No.</div>
          </div>
        </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
          <div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div>
          </div>
        </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20009213x3_ex1-1.htm">1.1</a></div>
        </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Underwriting Agreement, dated May 24, 2023, by and between U.S. Physical Therapy, Inc. and BofA Securities, Inc. and J.P. Morgan Securities LLC, as
            representatives of the several underwriters named therein.</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20009213x3_ex5-1.htm">5.1</a></div>
        </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Opinion of Woodburn and Wedge, Chartered, as to the validity of the Offered Shares.</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20009213x3_ex5-1.htm">23.1</a></div>
        </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Consent of Woodburn and Wedge, Chartered (included in Exhibit 5.1).</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20009213x3_ex99-1.htm">99.1</a></div>
        </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Press Release, dated May 23, 2023.</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20009213x3_ex99-2.htm">99.2</a></div>
        </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Press Release, dated May 24, 2023.</div>
        </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
        </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Data File (embedded within the inline XBRL document)</div>
        </td>

  </tr>


</table>
  <div><br />
  </div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

  </div>

  <div><br />
  </div>

  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

  <div><br />
  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
    hereunto duly authorized.</div>

  <div><br />
  </div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date: May 25, 2023</div>

  <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span><br />
  </div>

  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="vertical-align: top;" colspan="3">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">U.S. PHYSICAL THERAPY, INC.</div>
        </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: middle;">&#160;</td>

    <td style="vertical-align: middle;" colspan="2">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
        </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 44%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
          <div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Carey Hendrickson</div>
          </div>
        </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name:</div>
        </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 44%; vertical-align: bottom;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carey Hendrickson</div>
        </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title:</div>
        </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 44%; vertical-align: bottom;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Chief Financial Officer</div>
        </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 44%; vertical-align: bottom;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(duly authorized officer and principal financial and accounting officer)</div>
        </td>

  </tr>


</table>
  <div>
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /> </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ny20009213x3_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">
  <p style="margin: 0"></p>
  <!-- Field: Rule-Page --><!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p>
  <!-- Field: Rule-Page -->
  <div align="CENTER">
    <div style="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit 1.1&#160;</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>
  <table cellspacing="0" cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%; border-top: Black 1pt solid; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">U.S. Physical Therapy, Inc.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a Nevada corporation)</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,666,667 Shares of Common Stock</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>UNDERWRITING AGREEMENT</u></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: May 24, 2023</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
  <table cellspacing="0" cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%; border-top: Black 1pt solid; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <!-- Field: Rule-Page --><!-- Field: /Rule-Page -->
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><br>
  </p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. Physical Therapy, Inc.</font></p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a Nevada corporation)</font></p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,666,667 Shares of Common Stock</font></p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNDERWRITING AGREEMENT</font></p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 24, 2023</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-indent: -58.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BofA Securities, Inc.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-indent: -58.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.P. Morgan Securities LLC</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as Representatives of the several Underwriters</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c/o BofA Securities, Inc.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One Bryant Park<br>
      New York, New York 10036</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c/o J.P. Morgan Securities LLC</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">383 Madison Avenue</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, New York 10179</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies and Gentlemen:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. Physical Therapy, Inc., a Nevada corporation (the &#8220;Company&#8221;),
      confirms its agreement with BofA Securities, Inc. (&#8220;BofA&#8221;), J.P. Morgan Securities LLC (&#8220;J.P. Morgan&#8221;) and each of the other Underwriters named in <u>Schedule A</u> hereto (collectively, the &#8220;Underwriters,&#8221; which term shall also include any
      underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA and J.P. Morgan are acting as representatives (in such capacity, the &#8220;Representatives&#8221;), with respect to (i) the sale by the Company and the purchase by the
      Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.01 per share, of the Company (&#8220;Common Stock&#8221;) set forth in <u>Schedule A</u> hereto and (ii) the grant by the Company to the
      Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 250,000 additional shares of Common Stock. The aforesaid 1,666,667 shares of Common Stock (the &#8220;Initial Securities&#8221;) to be
      purchased by the Underwriters and all or any part of the 250,000 shares of Common Stock subject to the option described in Section 2(b) hereof (the &#8220;Option Securities&#8221;) are herein called, collectively, the &#8220;Securities.&#8221;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company understands that the Underwriters propose to make a public
      offering of the Securities as soon as the Representatives deem advisable after this Agreement has been executed and delivered.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has prepared and filed with the Securities and Exchange
      Commission (the &#8220;Commission&#8221;) an automatic shelf registration statement on Form S-3 (File No. 333-272147) covering the public offering and sale of certain securities, including the Securities, under the Securities Act of 1933, as amended (the &#8220;1933
      Act&#8221;), and the rules and regulations promulgated thereunder (the &#8220;1933 Act Regulations&#8221;), which automatic shelf registration statement became effective under Rule 462(e) under the 1933 Act Regulations (&#8220;Rule 462(e)&#8221;). Such registration statement, as
      of any time, means such registration statement as amended by any post-effective amendments thereto to such time, including the exhibits and any schedules thereto at such time, the documents incorporated or deemed to be incorporated by reference
      therein at such time pursuant to Item 12 of Form S-3 under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to Rule 430B under the 1933 Act Regulations (&#8220;Rule 430B&#8221;), is referred to herein as the
      &#8220;Registration Statement;&#8221; provided, however, that the &#8220;Registration Statement&#8221; without reference to a time means such registration statement as amended by any post-effective amendments thereto as of the time of the first contract of sale for the
      Securities, which time shall be considered the &#8220;new effective date&#8221; of such registration statement with respect to the Securities within the meaning of paragraph (f)(2) of Rule 430B, including the exhibits and schedules thereto as of such time, the
      documents incorporated or deemed incorporated by reference therein at such time pursuant to Item 12 of Form S-3 under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to the Rule 430B. Each preliminary
      prospectus supplement used in connection with the offering of the Securities, including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form S-3 under the 1933 Act, are collectively referred to
      herein as a &#8220;preliminary prospectus.&#8221; Promptly after execution and delivery of this Agreement, the Company will prepare and file a final prospectus supplement relating to the Securities in accordance with the provisions of Rule 424(b) under the 1933
      Act Regulations (&#8220;Rule 424(b)&#8221;). The final prospectus supplement, in the form first furnished or made available to the Underwriters for use in connection with the offering of the Securities, including the documents incorporated or deemed to be
      incorporated by reference therein pursuant to Item 12 of Form S-3 under the 1933 Act, are collectively referred to herein as the &#8220;Prospectus.&#8221; For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus,
      the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system (or any successor system)(&#8220;EDGAR&#8221;).</font></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <!--PROfilePageNumberReset%Num%2%%%-->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As used in this Agreement:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Applicable Time&#8221; means 6:00 P.M., New York City time, on May
      24, 2023 or such other time as agreed by the Company and the Representatives.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;General Disclosure Package&#8221; means any Issuer General Use Free
      Writing Prospectuses issued at or prior to the Applicable Time, the most recent preliminary prospectus (including any documents incorporated therein by reference) that is distributed to investors prior to the Applicable Time and the information
      included on <u>Schedule B-1</u> hereto, all considered together.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Issuer Free Writing Prospectus&#8221; means any &#8220;issuer free
      writing prospectus,&#8221; as defined in Rule 433 of the 1933 Act Regulations (&#8220;Rule 433&#8221;), including without limitation any &#8220;free writing prospectus&#8221; (as defined in Rule 405 of the 1933 Act Regulations (&#8220;Rule 405&#8221;)) relating to the Securities that is (i)
      required to be filed with the Commission by the Company, (ii) a &#8220;road show that is a written communication&#8221; within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or (iii) exempt from filing with the
      Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Securities or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to
      be filed, in the form retained in the Company&#8217;s records pursuant to Rule 433(g).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Issuer General Use Free Writing Prospectus&#8221; means any Issuer
      Free Writing Prospectus that is intended for general distribution to prospective investors (other than a &#8220;<i>bona fide</i> electronic road show,&#8221; as defined in Rule 433), as evidenced by its being specified in <u>Schedule B-2</u> hereto.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Issuer Limited Use Free Writing Prospectus&#8221; means any Issuer
      Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.</font></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">2</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All references in this Agreement to financial statements and schedules
      and other information which is &#8220;contained,&#8221; &#8220;included&#8221; or &#8220;stated&#8221; (or other references of like import) in the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include all such financial statements and schedules
      and other information incorporated or deemed incorporated by reference in the Registration Statement, any preliminary prospectus or the Prospectus, as the case may be, prior to the execution and delivery of this Agreement; and all references in this
      Agreement to amendments or supplements to the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include the filing of any document under the Securities Exchange Act of 1934, as amended, and the rules and
      regulations promulgated thereunder (collectively, the &#8220;1934 Act&#8221;), incorporated or deemed to be incorporated by reference in the Registration Statement, such preliminary prospectus or the Prospectus, as the case may be, at or after the execution and
      delivery of this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 1. <u>Representations and Warranties</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <i>Representations and Warranties by the Company</i>. The Company
      represents and warrants to each Underwriter as of the date hereof, the Applicable Time, the Closing Time (as defined below) and any Date of Delivery (as defined below), and agrees with each Underwriter, as follows:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) <u>Registration Statement and Prospectuses</u>. The Company meets the
      requirements for use of Form S-3 under the 1933 Act. The Registration Statement is an &#8220;automatic shelf registration statement&#8221; (as defined in Rule 405) and the Securities have been and remain eligible for registration by the Company on such automatic
      shelf registration statement. Each of the Registration Statement and any post-effective amendment thereto has become effective under the 1933 Act. No stop order suspending the effectiveness of the Registration Statement or any post-effective
      amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to
      the Company&#8217;s knowledge, contemplated. The Company has complied with each request (if any) from the Commission for additional information.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of the Registration Statement and any post-effective
      amendment thereto, at the time of its effectiveness, each deemed effective date with respect to the Underwriters pursuant to Rule 430B(f)(2) under the 1933 Act Regulations, the Applicable Time, the Closing Time and any Date of Delivery complied and
      will comply in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus, the Prospectus and any amendment or supplement thereto, at the time each was filed with the Commission, and, in each
      case, at the Applicable Time, the Closing Time and any Date of Delivery complied and will comply in all material respects with the requirements of the 1933 Act Regulations and each preliminary prospectus and the Prospectus delivered to the
      Underwriters for use in connection with this offering was identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The documents incorporated or deemed to be incorporated by
      reference in the Registration Statement and the Prospectus, when they became effective or at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the 1934 Act and
      the rules and regulations of the Commission under the 1934 Act (the &#8220;1934 Act Regulations&#8221;).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) <u>Accurate Disclosure</u>. Neither the Registration Statement nor
      any amendment thereto, at its effective time, on the date hereof, at the Closing Time or at any Date of Delivery, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact
      required to be stated therein or necessary to make the statements therein not misleading. At the Applicable Time and any Date of Delivery, neither (A) the General Disclosure Package nor (B) any individual Issuer Limited Use Free Writing Prospectus,
      when considered together with the General Disclosure Package, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the
      light of the circumstances under which they were made, not misleading. Neither the Prospectus nor any amendment or supplement thereto, as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b), at the Closing Time or
      at any Date of Delivery, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under
      which they were made, not misleading. The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, at the time the Registration Statement became effective or
      when such documents incorporated by reference were filed with the Commission, as the case may be, when read together with the other information in the Registration Statement, the General Disclosure Package or the Prospectus, as the case may be, did
      not and will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.</font></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">3</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The representations and warranties in this subsection shall
      not apply to statements in or omissions from the Registration Statement (or any amendment thereto), the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) made in reliance upon and in conformity with written
      information furnished to the Company by any Underwriter through the Representatives expressly for use therein. For purposes of this Agreement, the only information so furnished shall be the information in the first paragraph under the heading
      &#8220;Underwriting&#8211;Commissions and Discounts&#8221; and the information in the second, third and fourth paragraphs under the heading &#8220;Underwriting&#8211;Price Stabilization, Short Positions and Penalty Bids,&#8221; in each case contained in the Prospectus (collectively,
      the &#8220;Underwriter Information&#8221;).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) <u>Issuer Free Writing Prospectuses</u>. No Issuer Free Writing
      Prospectus conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein, and any preliminary or other prospectus deemed to be a part thereof that
      has not been superseded or modified. Any offer that is a written communication relating to the Securities made prior to the initial filing of the Registration Statement by the Company or any person acting on its behalf (within the meaning, for this
      paragraph only, of Rule 163(c) of the 1933 Act Regulations) has been filed with the Commission in accordance with the exemption provided by Rule 163 under the 1933 Act Regulations (&#8220;Rule 163&#8221;) and otherwise complied with the requirements of Rule 163,
      including without limitation the legending requirement, to qualify such offer for the exemption from Section 5(c) of the 1933 Act provided by Rule 163.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) <u>Well-Known Seasoned Issuer.</u> (A) At the original effectiveness
      of the Registration Statement, (B) at the time of the most recent amendment thereto for the purposes of complying with Section 10(a)(3) of the 1933 Act (whether such amendment was by post-effective amendment, incorporated report filed pursuant to
      Section 13 or 15(d) of the 1934 Act or form of prospectus), (C) at the time the Company or any person acting on its behalf (within the meaning, for this clause only, of Rule 163(c) under the 1933 Act) made any offer relating to the Securities in
      reliance on the exemption of Rule 163 under the 1933 Act, and (D) as of the Applicable Time, the Company was and is a &#8220;well-known seasoned issuer&#8221; (as defined in Rule 405).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) <u>Company Not Ineligible Issuer</u>. At the time of filing the
      Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or another offering participant made a <i>bona fide</i> offer (within the meaning of Rule 164(h)(2) of the 1933 Act Regulations) of the
      Securities and at the date hereof, the Company was not and is not an &#8220;ineligible issuer,&#8221; as defined in Rule 405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be
      considered an ineligible issuer.</font></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">4</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi) <u>Independent Accountants</u>. The accountants who certified the
      financial statements and supporting schedules included in the Registration Statement, the General Disclosure Package and the Prospectus are independent public accountants as required by the 1933 Act, the 1933 Act Regulations, the 1934 Act, the 1934
      Act Regulations and the Public Company Accounting Oversight Board.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii) <u>Financial Statements; Non-GAAP Financial Measures</u>. The
      financial statements included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, together with the related schedules and notes, present fairly in all material respects the financial position
      of the Company and its consolidated subsidiaries at the dates indicated and the statement of operations, stockholders&#8217; equity and cash flows of the Company and its consolidated subsidiaries for the periods specified; said financial statements have
      been prepared in conformity in all material respects with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) applied on a consistent basis throughout the periods involved, expect as otherwise disclosed in the General Disclosure Package. The
      supporting schedules, if any, present fairly in accordance with GAAP in all material respects the information required to be stated therein. The selected financial data and the summary financial information included in the Registration Statement, the
      General Disclosure Package and the Prospectus present fairly the information shown therein and have been compiled on a basis consistent with that of the audited financial statements included therein. Except as included therein, no historical or pro
      forma financial statements or supporting schedules are required to be included or incorporated by reference in the Registration Statement, the General Disclosure Package or the Prospectus under the 1933 Act or the 1933 Act Regulations. All
      disclosures contained in the Registration Statement, the General Disclosure Package or the Prospectus, or incorporated by reference therein, regarding &#8220;non-GAAP financial measures&#8221; (as such term is defined by the rules and regulations of the
      Commission) comply with Regulation G of the 1934 Act and Item 10 of Regulation S-K of the 1933 Act, to the extent applicable. The interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement, the
      General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii) <u>No Material Adverse Change in Business</u>. Except as otherwise
      stated therein, since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, (A) there has been no material adverse change in the condition, financial or otherwise, or in
      the earnings, business affairs, business prospects or properties of the Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business (a &#8220;Material Adverse Effect&#8221;), (B) there have been no
      transactions entered into by the Company or any of its subsidiaries, other than those in the ordinary course of business, which are material with respect to the Company and its subsidiaries considered as one enterprise, and (C) except for regular
      quarterly dividends on the Common Stock in amounts per share that are consistent with past practice, there has been no dividend or distribution of any kind declared, paid or made by the Company on any class of its capital stock.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix) <u>Good Standing of the Company</u>. The Company has been duly
      organized and is validly existing as a corporation in good standing under the laws of the State of Nevada and has corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration
      Statement, the General Disclosure Package and the Prospectus and to enter into and perform its obligations under this Agreement; and the Company is duly qualified as a foreign corporation to transact business and is in good standing in each other
      jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure so to qualify or to be in good standing would not result in a Material Adverse
      Effect.</font></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">5</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x) <u>Good Standing of Subsidiaries</u>. Each &#8220;significant subsidiary&#8221;
      of the Company (as such term is defined in Rule 1-02 of Regulation S-X) (each, a &#8220;Subsidiary&#8221; and, collectively, the &#8220;Subsidiaries&#8221;) has been duly organized and is validly existing in good standing under the laws of the jurisdiction of its
      incorporation or organization, has corporate or similar power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and is duly
      qualified to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to so qualify or to be
      in good standing would not result in a Material Adverse Effect. Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, all of the issued and outstanding capital stock of each Subsidiary has
      been duly authorized and validly issued, is fully paid and non-assessable and is owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim or equity. None of the
      outstanding shares of capital stock of any Subsidiary were issued in violation of the preemptive or similar rights of any securityholder of such Subsidiary. The only subsidiaries of the Company are the subsidiaries listed on Exhibit 21.1 to the
      Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi) <u>Capitalization</u>. The outstanding shares of capital stock of
      the Company have been duly authorized and validly issued and are fully paid and non-assessable. None of the outstanding shares of capital stock of the Company were issued in violation of the preemptive or other similar rights of any securityholder of
      the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii) <u>Authorization of Agreement</u>. This Agreement has been duly
      authorized, executed and delivered by the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii) <u>Authorization and Description of Securities</u>. The Securities
      to be purchased by the Underwriters from the Company have been duly authorized for issuance and sale to the Underwriters pursuant to this Agreement and, when issued and delivered by the Company pursuant to this Agreement against payment of the
      consideration set forth herein, will be validly issued and fully paid and non-assessable; and the issuance of the Securities is not subject to the preemptive or other similar rights of any securityholder of the Company. The Common Stock conforms to
      all statements relating thereto contained in the Registration Statement, the General Disclosure Package and the Prospectus and such description conforms to the rights set forth in the instruments defining the same. No holder of Securities will be
      subject to personal liability by reason of being such a holder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv) <u>Registration Rights</u>. There are no persons with registration
      rights or other similar rights to have any securities registered for sale pursuant to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933 Act pursuant to this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv) <u>Absence of Violations, Defaults and Conflicts</u>. Neither the
      Company nor any of its subsidiaries is (A) in violation of its charter, by-laws or similar organizational document, (B) in default in the performance or observance of any obligation, agreement, covenant or condition contained in any contract,
      indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound or to which any of the properties or
      assets of the Company or any subsidiary is subject (collectively, &#8220;Agreements and Instruments&#8221;), except for such defaults that would not, singly or in the aggregate, result in a Material Adverse Effect, or (C) in violation of any law, statute, rule,
      regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company or any of its subsidiaries or any of their
      respective properties, assets or operations (each, a &#8220;Governmental Entity&#8221;), except for such violations that would not, singly or in the aggregate, result in a Material Adverse Effect. The execution, delivery and performance of this Agreement and the
      consummation of the transactions contemplated herein and in the Registration Statement, the General Disclosure Package and the Prospectus (including the issuance and sale of the Securities and the use of the proceeds from the sale of the Securities
      as described therein under the caption &#8220;Use of Proceeds&#8221;) and compliance by the Company with its obligations hereunder have been duly authorized by all necessary corporate action and do not and will not, whether with or without the giving of notice
      or passage of time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any properties or assets of the Company or
      any subsidiary pursuant to, the Agreements and Instruments (except for such conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances that would not, singly or in the aggregate, result in a Material Adverse Effect), nor will
      such action result in any violation of the provisions of the charter, by-laws or similar organizational document of the Company or any of its subsidiaries or any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental
      Entity. As used herein, a &#8220;Repayment Event&#8221; means any event or condition which gives the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#8217;s behalf) the right to require the repurchase, redemption or
      repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries.</font></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">6</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi) <u>Absence of Labor Dispute</u>. No labor dispute with the
      employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or any subsidiary&#8217;s principal
      suppliers, manufacturers, customers or contractors, which, in either case, would result in a Material Adverse Effect.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvii) <u>Absence of Proceedings</u>. Except as disclosed in the
      Registration Statement, the General Disclosure Package and the Prospectus, there is no action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity now pending or, to the knowledge of the Company, threatened,
      against or affecting the Company or any of its subsidiaries, which might result in a Material Adverse Effect, or which might materially and adversely affect their respective properties or assets or the consummation of the transactions contemplated in
      this Agreement or the performance by the Company of its obligations hereunder; and the aggregate of all pending legal or governmental proceedings to which the Company or any such subsidiary is a party or of which any of their respective properties or
      assets is the subject which are not described in the Registration Statement, the General Disclosure Package and the Prospectus, including ordinary routine litigation incidental to the business, could not result in a Material Adverse Effect.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xviii) <u>Accuracy of Exhibits</u>. There are no contracts or documents
      which are required to be described in the Registration Statement, the General Disclosure Package or the Prospectus or to be filed as exhibits to the Registration Statement which have not been so described and filed as required.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xix) <u>Absence of Further Requirements</u>. No filing with, or
      authorization, approval, consent, license, order, registration, qualification or decree of, any Governmental Entity is necessary or required for the performance by the Company of its obligations hereunder, in connection with the offering, issuance or
      sale of the Securities hereunder or the consummation of the transactions contemplated by this Agreement, except such as have been already obtained or as may be required under the 1933 Act, the 1933 Act Regulations, the rules of the New York Stock
      Exchange, state securities laws or the rules of Financial Industry Regulatory Authority, Inc. (&#8220;FINRA&#8221;).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xx) <u>Possession of Licenses and Permits</u>. The Company and its
      subsidiaries possess such permits, licenses, approvals, consents, provider or supplier numbers, accreditations, certificates, exemptions and other authorizations (collectively, &#8220;Governmental Licenses&#8221;) issued by the appropriate Governmental Entities
      necessary to conduct the business now operated by them, except where the failure so to possess would not, singly or in the aggregate, result in a Material Adverse Effect. The Company and its subsidiaries are in compliance with the terms and
      conditions of all Governmental Licenses, except where the failure so to comply would not, singly or in the aggregate, result in a Material Adverse Effect. All of the Governmental Licenses are valid and in full force and effect, except when the
      invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in full force and effect would not, singly or in the aggregate, result in a Material Adverse Effect. Neither the Company nor any of its subsidiaries has
      received any notice of proceedings relating to the revocation or modification of any Governmental Licenses which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Effect.</font></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">7</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxi) <u>Title to Property</u>. The Company and its subsidiaries have
      good and marketable title to all real property owned by them and good title to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions or encumbrances of any kind
      except such as (A) are described in the Registration Statement, the General Disclosure Package and the Prospectus or (B) do not, singly or in the aggregate, materially affect the value of such property and do not materially interfere with the use
      made and proposed to be made of such property by the Company or any of its subsidiaries; and all of the leases and subleases material to the business of the Company and its subsidiaries, considered as one enterprise, and under which the Company or
      any of its subsidiaries holds properties described in the Registration Statement, the General Disclosure Package or the Prospectus, are in full force and effect, and neither the Company nor any such subsidiary has any notice of any material claim of
      any sort that has been asserted by anyone adverse to the rights of the Company or any subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such subsidiary to the continued
      possession of the leased or subleased premises under any such lease or sublease.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxii) <u>Possession of Intellectual Property</u>. The Company and its
      subsidiaries own or possess, or can acquire on reasonable terms, adequate patents, patent rights, licenses, inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information,
      systems or procedures), trademarks, service marks, trade names or other intellectual property (collectively, &#8220;Intellectual Property&#8221;) necessary to carry on the business now operated by them, and neither the Company nor any of its subsidiaries has
      received any notice or is otherwise aware of any infringement of or conflict with asserted rights of others with respect to any Intellectual Property or of any facts or circumstances which would render any Intellectual Property invalid or inadequate
      to protect the interest of the Company or any of its subsidiaries therein, and which infringement or conflict (if the subject of any unfavorable decision, ruling or finding) or invalidity or inadequacy, singly or in the aggregate, would result in a
      Material Adverse Effect.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxiii) <u>Environmental Laws</u>. Except as described in the
      Registration Statement, the General Disclosure Package and the Prospectus or would not, singly or in the aggregate, result in a Material Adverse Effect, (A) neither the Company nor any of its subsidiaries is in violation of any federal, state, local
      or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or
      protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or
      threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing materials or mold (collectively, &#8220;Hazardous Materials&#8221;) or to the manufacture, processing,
      distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#8220;Environmental Laws&#8221;), (B) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable
      Environmental Laws and are each in compliance with their requirements, (C) there are no pending or threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation,
      investigations or proceedings relating to any Environmental Law against the Company or any of its subsidiaries and (D) there are no events or circumstances that would reasonably be expected to form the basis of an order for clean-up or remediation,
      or an action, suit or proceeding by any private party or Governmental Entity, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws.</font></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">8</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxiv) <u>Accounting Controls and Disclosure Controls</u>. The Company
      and each of its subsidiaries maintain effective internal control over financial reporting (as defined under Rule 13-a15 and 15d-15 under the 1934 Act Regulations) and a system of internal accounting controls sufficient to provide reasonable
      assurances that (A) transactions are executed in accordance with management&#8217;s general or specific authorization; (B) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain
      accountability for assets; (C) access to assets is permitted only in accordance with management&#8217;s general or specific authorization; (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and
      appropriate action is taken with respect to any differences; and (E) the interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly
      presents the information called for in all material respects and is prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto. Except as described in the Registration Statement, the General Disclosure Package and the
      Prospectus, since the end of the Company&#8217;s most recent audited fiscal year, there has been (1) no material weakness in the Company&#8217;s internal control over financial reporting (whether or not remediated) and (2) no change in the Company&#8217;s internal
      control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company and each of its subsidiaries maintain an effective system of disclosure
      controls and procedures (as defined in Rule 13a-15 and Rule 15d-15 under the 1934 Act Regulations) that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is
      recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms, and is accumulated and communicated to the Company&#8217;s management, including its principal executive officer or officers and principal
      financial officer or officers, as appropriate, to allow timely decisions regarding disclosure.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxv) <u>Compliance with the Sarbanes-Oxley Act.</u> There is and has
      been no failure on the part of the Company or any of the Company&#8217;s directors or officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated
      in connection therewith, including Section 402 related to loans and Sections 302 and 906 related to certifications.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxvi) <u>Payment of Taxes</u>. All United States federal income tax
      returns of the Company and its subsidiaries required by law to be filed have been filed, or valid extensions have been requested therefor, and all taxes shown by such returns or otherwise assessed, which are due and payable, have been paid, except
      assessments against which appeals have been or will be promptly taken and as to which adequate reserves have been provided. No assessment in connection with the United States federal income tax returns of the Company for the fiscal year ended
      December 31, 2022 have been made against the Company. The Company and its subsidiaries have filed all other tax returns that are required to have been filed by them pursuant to applicable foreign, state, local or other law except insofar as the
      failure to file such returns would not result in a Material Adverse Effect, and has paid all taxes due pursuant to such returns or pursuant to any assessment received by the Company and its subsidiaries, except for such taxes, if any, as are being
      contested in good faith and as to which adequate reserves have been established by the Company. The charges, accruals and reserves on the books of the Company in respect of any income and corporation tax liability for any years not finally determined
      are adequate to meet any assessments or re-assessments for additional income tax for any years not finally determined, except to the extent of any inadequacy that would not result in a Material Adverse Effect.</font></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">9</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxvii) <u>Insurance</u>. The Company and its subsidiaries carry or are
      entitled to the benefits of insurance, with financially sound and reputable insurers, in such amounts and covering such risks as is generally maintained by companies of established repute engaged in the same or similar business, and all such
      insurance is in full force and effect. The Company has no reason to believe that it or any of its subsidiaries will not be able (A) to renew its existing insurance coverage as and when such policies expire or (B) to obtain comparable coverage from
      similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Effect. Neither of the Company nor any of its subsidiaries has been denied any insurance
      coverage which it has sought or for which it has applied.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxviii) <u>Investment Company Act</u>. The Company is not required, and
      upon the issuance and sale of the Securities as herein contemplated and the application of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and the Prospectus will not be required, to register as
      an &#8220;investment company&#8221; under the Investment Company Act of 1940, as amended (the &#8220;1940 Act&#8221;).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxix) <u>Absence of Manipulation</u>. Neither the Company nor any
      affiliate of the Company has taken, nor will the Company or any affiliate take, directly or indirectly, any action which is designed, or would be expected, to cause or result in, or which constitutes, the stabilization or manipulation of the price of
      any security of the Company to facilitate the sale or resale of the Securities or to result in a violation of Regulation M under the 1934 Act.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxx) <u>Foreign Corrupt Practices Act</u>. None of the Company, any of
      its subsidiaries, any director or officer or, to the knowledge of the Company, any agent, employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries is aware of or has taken any action, directly or indirectly, that
      would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the &#8220;FCPA&#8221;), including, without limitation, making use of the mails or any means or instrumentality of
      interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any &#8220;foreign official&#8221;
      (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA and the Company and, to the knowledge of the Company, its affiliates have conducted
      their businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxi) <u>Money Laundering Laws</u>. The operations of the Company and
      its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of
      all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &#8220;Money Laundering Laws&#8221;); and no action, suit or
      proceeding by or before any Governmental Entity involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxii) <u>OFAC</u>. None of the Company, any of its subsidiaries, any
      director or officer or, to the knowledge of the Company, any agent, employee, affiliate or representative of the Company or any of its subsidiaries is an individual or entity (&#8220;Person&#8221;) currently the subject or target of any sanctions administered or
      enforced by the United States Government, including, without limitation, the U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control (&#8220;OFAC&#8221;), the United Nations Security Council (&#8220;UNSC&#8221;), the European Union, His Majesty&#8217;s Treasury
      (&#8220;HMT&#8221;), or other relevant sanctions authority (collectively, &#8220;Sanctions&#8221;), nor is the Company located, organized or resident in a country or territory that is the subject of Sanctions including, without limitation, the so-called Donetsk People&#8217;s
      Republic, the so-called Luhansk People&#8217;s Republic, and the Crimea regions of Ukraine, Cuba, Iran, North Korea and Syria or any other region of Ukraine identified pursuant to Executive Order 14065 (each, a &#8220;Sanctioned Country/Territory&#8221;); and the
      Company will not directly or indirectly use the proceeds of the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, to fund any activities of or business
      with any Person, or in any country or territory, that, at the time of such funding, is the subject of Sanctions or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as
      underwriter, advisor, investor or otherwise) of Sanctions.</font></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">10</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxiii) <u>Lending Relationship</u><i>. </i>Except as disclosed in the
      Registration Statement, the General Disclosure Package and the Prospectus, the Company (i) does not have any material lending or other relationship with any bank or lending affiliate of any Underwriter and (ii) does not intend to use any of the
      proceeds from the sale of the Securities to repay any outstanding debt owed to any affiliate of any Underwriter.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxiv) <u>Statistical and Market-Related Data</u>. Any statistical and
      market-related data included in the Registration Statement, the General Disclosure Package or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate and, to the extent
      required, the Company has obtained the written consent to the use of such data from such sources.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxv) <u>Cybersecurity</u>. (A) There has been no security breach or
      incident, unauthorized access or disclosure, or other compromise of or relating to the Company or its subsidiaries information technology and computer systems, networks, hardware, software, data and databases (including the data and information of
      their respective customers, employees, suppliers, vendors and any third party data maintained, processed or stored by the Company and its subsidiaries, and any such data processed or stored by third parties on behalf of the Company and its
      subsidiaries), equipment or technology (collectively, &#8220;IT Systems and Data&#8221;): (B) neither the Company nor any of its subsidiaries have been notified of, and each of them have no knowledge of any event or condition that could result in, any security
      breach or incident, unauthorized access or disclosure or other compromise to their IT Systems and Data and (C) the Company and its subsidiaries have implemented appropriate controls, policies, procedures, and technological safeguards to maintain and
      protect the integrity, continuous operation, redundancy and security of their IT Systems and Data reasonably consistent with industry standards and practices, or as required by applicable regulatory standards. The Company and its subsidiaries are,
      and have been, in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to
      the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxvi) <u>Healthcare Laws</u>. Except as disclosed in the Registration
      Statement, the General Disclosure Package or the Prospectus, or where the failure to comply would not be expected, singly or in the aggregate, to result in a Material Adverse Effect, each of the Company and its subsidiaries is and has been in
      compliance with all applicable Healthcare Laws (as defined below), and has not engaged in activities which could provide, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid,
      or any other state health care program or federal health care program. The term &#8220;Healthcare Laws&#8221; shall include any applicable federal, state, local or foreign statute, law, rule, guidance, regulation, ordinance, code, policy or rule of common law or
      any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to healthcare services, reimbursement, fraud and abuse, conditions for participation, or the privacy,
      security, use and disclosure of individually identifiable health information, including: Title XVIII of the Social Security Act, 42 U.S.C. &#167;&#167; 1395-1395hhh (the Medicare statute), including the Ethics in Patient Referrals Act, as amended (the Stark
      Law), 42 U.S.C. &#167; 1395nn; Title XIX of the Social Security Act, 42 U.S.C. &#167;&#167; 1396-1396v (the Medicaid statute); the Federal Health Care Program Anti-Kickback Statute, 42 U.S.C. &#167; 1320a-7b(b); the False Claims Act, 31 U.S.C. &#167;&#167; 3729-3733 (as amended);
      the Program Fraud Civil Remedies Act, 31 U.S.C. &#167;&#167; 3801-3812; the Anti-Kickback Act of 1986, 41 U.S.C. &#167;&#167; 51-58; the Civil Monetary Penalties Law, 42 U.S.C. &#167;&#167; 1320a-7a and 1320a-7b; the Exclusion Laws, 42 U.S.C. &#167; 1320a-7; TRICARE, 10 U.S.C. &#167; 1071
      et seq.; the Health Insurance Portability and Accountability Act of 1996, 42 U.S.C. &#167;&#167; 1320d-1329d-8, as amended by the Health Information Technology for Economic and Clinical Health Act, enacted as Title XIII of the American Recovery and
      Reinvestment Act of 2009, Public Law 111-5, including but not limited to the regulations implemented thereunder at 45 C.F.R. Parts 160 and 164, and any similar state and local laws; any criminal laws relating to health care fraud and abuse, including
      but not limited to 18 U.S.C. Sections 286, 287, 1035, 1347 and 1349; any applicable state fraud and abuse prohibitions, including those that apply to all payors (governmental, commercial insurance and self-payors); the Eliminating Kickbacks in
      Recovery Act of 2018, 18 U.S.C. &#167; 220; the Families First Coronavirus Response Act (P.L. 116-127), the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139), the Coronavirus Aid, Relief, and Economic Security (P.L. 116-136), the
      Coronavirus Response and Relief Supplemental Appropriations Act (P.L. 116-260) and the American Rescue Plan Act of 2021 (P.L. 117-2); any other law or regulation that relates to or governs a government healthcare program; all applicable federal,
      state, and local licensing, data privacy and security, corporate practice of physical therapy, supervision, scope of care, concurrent therapy, fee splitting, anti-kickback or self-referral, regulatory and reimbursement laws or other legally binding
      requirements; and regulations promulgated pursuant to such laws. Except as set forth in the Registration Statement, the General Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries has received written notice from
      any Governmental Entity of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action alleging that the Company or its subsidiaries is in material violation of any Healthcare Laws, and, to the Company&#8217;s
      knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened. Except as set forth in the Registration Statement, the General Disclosure Package or the Prospectus, neither the
      Company nor any of its subsidiaries is a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred or non-prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of
      correction or similar agreements with or imposed by any Governmental Entity. Additionally, neither the Company or any of its subsidiaries, or any of their respective employees, officers or directors has been excluded, suspended or debarred from
      participation in any U.S. federal health care program or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension,
      or exclusion.</font></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">11</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxvii) <u>Program Participation</u>. Except as set forth in the
      Registration Statement, the General Disclosure Package or the Prospectus, the Company and its subsidiaries, as applicable, meet all material requirements of participation of the Programs (as defined below) and are a party to valid participation
      agreements for payment by such Programs. Neither the Company nor any of its subsidiaries has received notice from any of the Programs of any pending or threatened investigations that would result in exclusion or debarment from any such Programs or
      the termination of any third-party payment program participation agreement. &#8220;Programs&#8221; shall mean Medicare, Medicaid, TRICARE, any other local, state or federal health care program, workers&#8217; compensation, private insurance companies, health
      maintenance organizations, preferred provider organizations, alternative delivery systems, managed care systems, government contracting agencies and any other third-party payors that the Company participates in.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxviii) <u>Program Claims and Filings</u>. Except as set forth in the
      Registration Statement, the General Disclosure Package or the Prospectus or except as would not be expected, singly or in the aggregate, to result in a Material Adverse Effect, all reports, data, and information required to be filed by the Company
      and its subsidiaries in connection with any Program have been timely filed and were true and complete at the time filed (or were corrected in or supplemented by a subsequent filing), accurately reflecting medically necessary services provided by the
      Company, any Clinical Partnership or subsidiary, as applicable, and documented in compliance with all applicable Healthcare Laws. Except as set forth in the Registration Statement, the General Disclosure Package or the Prospectus, there are no
      claims, actions or appeals pending (and the Company and its subsidiaries have not made any filing or submission that would result in any claims, actions or appeals) with respect to any Program reports or claims filed by the Company or any of its
      subsidiaries on or before the date hereof, or with respect to any disallowances by any Program in connection with any audit or any claims that, if adversely determined, which would not be expected, singly or in the aggregate, to result in a Material
      Adverse Effect. No validation review or program integrity review related to the Company or any of its subsidiaries has been conducted by any Governmental Entity or any Program within the past three (3) years which, if determined adversely to the
      Company or any of its subsidiaries, has had, or would not be expected, singly or in the aggregate, to result in a Material Adverse Effect, and to the Company&#8217;s knowledge, no such reviews are scheduled, pending, threatened against or affecting the
      Company or any of its subsidiaries. Except in the ordinary course of business or as set forth in the Registration Statement, the General Disclosure Package or the Prospectus, there are no material suspensions, offsets or recoupments of any Program
      being sought, requested or claimed, or to the knowledge of the Company, threatened against the Company or its subsidiaries.</font></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">12</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxix) <u>Company Providers</u>. Each of the Company and its
      subsidiaries is in material compliance with all applicable Healthcare Laws regarding the selection, deselection, and credentialing of contracted or employed physical therapists, other licensed providers and any other persons rendering services to
      patients (&#8220;HCPs&#8221;), including, but not limited to, verification of licensing status and eligibility for reimbursement under the Programs. Except as has not had, and would not be expected, singly or in the aggregate, to result in a Material Adverse
      Effect, each of the Company&#8217;s and its subsidiaries&#8217; contracted or employed HCPs is properly licensed, supervised, and hold appropriate clinical privileges, as applicable, for the services which they provide, and, with respect to HCPs that perform
      services eligible for reimbursement under any Program, are not debarred, suspended or excluded from any such Program.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <i>Officer&#8217;s Certificates</i>. Any certificate signed by any officer
      of the Company or any of its subsidiaries delivered to the Representatives or to counsel for the Underwriters shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 2. <u>Sale and Delivery to Underwriters; Closing</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <i>Initial Securities</i>. On the basis of the representations and
      warranties herein contained and subject to the terms and conditions herein set forth, the Company agrees to sell to each Underwriter and each Underwriter, severally and not jointly, agrees to purchase from the Company, at the price per share set
      forth in <u>Schedule A</u>, that proportion of the number of Initial Securities set forth in <u>Schedule A</u> opposite the name of such Underwriter, plus any additional number of Initial Securities which such Underwriter may become obligated to
      purchase pursuant to the provisions of Section 10 hereof, bears to the total number of Initial Securities, subject, in each case, to such adjustments among the Underwriters as the Representatives in their sole discretion shall make to eliminate any
      sales or purchases of fractional shares.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <i>Option Securities</i>. In addition, on the basis of the
      representations and warranties herein contained and subject to the terms and conditions herein set forth, the Company hereby grants an option to the Underwriters, severally and not jointly, to purchase up to an additional 250,000 shares of Common
      Stock, at the price per share set forth in <u>Schedule A</u>, less an amount per share equal to any dividends or distributions declared by the Company and payable on the Initial Securities but not payable on the Option Securities. The option hereby
      granted may be exercised for 30 days after the date hereof and may be exercised in whole or in part at any time from time to time upon notice by the Representatives to the Company setting forth the number of Option Securities as to which the several
      Underwriters are then exercising the option and the time and date of payment and delivery for such Option Securities. Any such time and date of delivery (a &#8220;Date of Delivery&#8221;) shall be determined by the Representatives, but shall not be later than
      seven full business days after the exercise of said option, nor in any event prior to the Closing Time. If the option is exercised as to all or any portion of the Option Securities, each of the Underwriters, acting severally and not jointly, will
      purchase that proportion of the total number of Option Securities then being purchased which the number of Initial Securities set forth in <u>Schedule A</u> opposite the name of such Underwriter bears to the total number of Initial Securities,
      subject, in each case, to such adjustments as the Representatives in their sole discretion shall make to eliminate any sales or purchases of fractional shares.</font></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">13</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <i>Payment</i>. Payment of the purchase price for, and delivery of
      certificates or security entitlements for, the Initial Securities shall be made at the offices of Latham &amp; Watkins LLP, or at such other place as shall be agreed upon by the Representatives and the Company, at 9:00 A.M. (New York City time) on
      the second (third, if the pricing occurs after 4:30 P.M. (New York City time) on any given day) business day after the date hereof (unless postponed in accordance with the provisions of Section 10), or such other time not later than ten business days
      after such date as shall be agreed upon by the Representatives and the Company (such time and date of payment and delivery being herein called &#8220;Closing Time&#8221;).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, in the event that any or all of the Option Securities are
      purchased by the Underwriters, payment of the purchase price for, and delivery of certificates or security entitlements for, such Option Securities shall be made at the above-mentioned offices, or at such other place as shall be agreed upon by the
      Representatives and the Company, on each Date of Delivery as specified in the notice from the Representatives to the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment shall be made to the Company by wire transfer of immediately
      available funds to a bank account designated by the Company, against delivery to the Representatives for the respective accounts of the Underwriters of certificates or security entitlements for the Securities to be purchased by them. It is understood
      that each Underwriter has authorized the Representatives, for its account, to accept delivery of, receipt for, and make payment of the purchase price for, the Initial Securities and the Option Securities, if any, which it has agreed to purchase. The
      Representatives, individually and not as representatives of the Underwriters, may (but shall not be obligated to) make payment of the purchase price for the Initial Securities or the Option Securities, if any, to be purchased by any Underwriter whose
      funds have not been received by the Closing Time or the relevant Date of Delivery, as the case may be, but such payment shall not relieve such Underwriter from its obligations hereunder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 3. <u>Covenants of the Company</u>. The Company covenants with
      each Underwriter as follows:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <i>Compliance with Securities Regulations and Commission Requests</i>.
      The Company, subject to Section 3(b), will comply with the requirements of Rule 430B, and will notify the Representatives immediately, and confirm the notice in writing, (i) when any post-effective amendment to the Registration Statement shall become
      effective or any amendment or supplement to the Prospectus shall have been filed, (ii) of the receipt of any comments from the Commission, (iii) of any request by the Commission for any amendment to the Registration Statement or any amendment or
      supplement to the Prospectus, including any document incorporated by reference therein or for additional information, (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any
      post-effective amendment or of any order preventing or suspending the use of any preliminary prospectus or the Prospectus, or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or
      threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the 1933 Act concerning the Registration Statement and (v) if the Company becomes the subject of a proceeding under Section 8A of the
      1933 Act in connection with the offering of the Securities. The Company will effect all filings required under Rule 424(b), in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such
      steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company
      will make every reasonable effort to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment. The Company shall pay the required Commission
      filing fees relating to the Securities within the time required by Rule 456(b)(1)(i) under the 1933 Act Regulations without regard to the proviso therein and otherwise in accordance with Rules 456(b) and 457(r) under the 1933 Act Regulations
      (including, if applicable, by updating the Filing Fee Table in accordance with Rule 456(b)(1)(ii) either in a post-effective amendment to the Registration Statement or on the cover page of a prospectus filed pursuant to Rule 424(b)).</font></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">14</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <i>Continued Compliance with Securities Laws</i>. The Company will
      comply with the 1933 Act, the 1933 Act Regulations, the 1934 Act and the 1934 Act Regulations so as to permit the completion of the distribution of the Securities as contemplated in this Agreement and in the Registration Statement, the General
      Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172 of the 1933 Act Regulations (&#8220;Rule 172&#8221;), would be) required by the 1933 Act to be delivered in
      connection with sales of the Securities, any event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i) amend the Registration Statement in order that the
      Registration Statement will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) amend or supplement the General Disclosure
      Package or the Prospectus in order that the General Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein
      not misleading in the light of the circumstances existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement the General Disclosure Package or the Prospectus, as the case may be, in order to
      comply with the requirements of the 1933 Act or the 1933 Act Regulations, the Company will promptly (A) give the Representatives notice of such event, (B) prepare any amendment or supplement as may be necessary to correct such statement or omission
      or to make the Registration Statement, the General Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representatives with copies of any such amendment
      or supplement and (C) file with the Commission any such amendment or supplement; provided that the Company shall not file or use any such amendment or supplement to which the Representatives or counsel for the Underwriters shall object. The Company
      will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably request. The Company has given the Representatives notice of any filings made pursuant to the 1934 Act or 1934 Act Regulations
      within 48 hours prior to the Applicable Time; the Company will give the Representatives notice of its intention to make any such filing from the Applicable Time to the Closing Time and will furnish the Representatives with copies of any such
      documents a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representatives or counsel for the Underwriters shall reasonably object.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <i>Delivery of Registration Statements</i>. The Company has furnished
      or will deliver to the Representatives and counsel for the Underwriters, without charge, signed copies of the Registration Statement as originally filed and each amendment thereto (including exhibits filed therewith or incorporated by reference
      therein and documents incorporated or deemed to be incorporated by reference therein) and signed copies of all consents and certificates of experts, and will also deliver to the Representatives, without charge, a conformed copy of the Registration
      Statement as originally filed and each amendment thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the electronically
      transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</font></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">15</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <title></title>
  <p style="margin: 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(d)&#160;<i>Delivery of Prospectuses</i>. The Company has delivered to each Underwriter, without charge, as many copies of each preliminary prospectus as
    such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the 1933 Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus relating to the
    Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request. The Prospectus and
    any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(e)&#160;<i>Blue Sky Qualifications</i>. The Company will use its best efforts, in cooperation with the Underwriters, to qualify the Securities for
    offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representatives may designate and to maintain such qualifications in effect so long as required to complete the distribution of
    the Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to
    subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(f)&#160;<i>Rule 158</i>. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally available to its
    securityholders as soon as practicable an earnings statement for the purposes of, and to provide to the Underwriters the benefits contemplated by, the last paragraph of Section 11(a) of the 1933 Act.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(g)&#160;<i>Use of Proceeds</i>. The Company will use the net proceeds received by it from the sale of the Securities in the manner specified in the
    Registration Statement, the General Disclosure Package and the Prospectus under &#8220;Use of Proceeds.&#8221;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(h)&#160;<i>Listing</i>. The Company will use its best efforts to effect and maintain the listing of the Securities on the New York Stock Exchange.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(i)&#160;<i>Restriction on Sale of Securities</i>. During a period of 90 days from the date of the Prospectus, the Company will not, without the prior
    written consent of BofA and J.P. Morgan, (i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise
    transfer or dispose of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or file any registration statement under the 1933 Act with respect to any of the foregoing or (ii) enter into any swap
    or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Common Stock, whether any such swap or transaction described in clause (i) or (ii) above is to be
    settled by delivery of Common Stock or other securities, in cash or otherwise; <i>provided</i> that confidential or non-public submissions to the Commission of any registration statements under the 1933 Act may be made if (w) no public announcement of
    such confidential or non-public submission shall be made, (x) if any demand was made for, or any right exercised with respect to, such registration of shares of Common Stock or securities convertible, exercisable or exchangeable into Common Stock, no
    public announcement of such demand or exercise of rights shall be made, (y) the Company shall provide written notice at least three business days prior to such confidential or non-public submission to BofA and J.P. Morgan and (z) no such confidential
    or non-public submission shall become a publicly filed registration statement during the 90-day restricted period. The foregoing sentence shall not apply to (A) the Securities to be sold hereunder, (B) any shares of Common Stock issued by the Company
    upon the exercise of an option or warrant or the conversion of a security outstanding on the date hereof and referred to in the Registration Statement, the General Disclosure Package and the Prospectus, (C) any shares of Common Stock issued or options
    to purchase Common Stock or other equity incentive awards granted pursuant to existing employee benefit, equity incentive or employee stock plans of the Company referred to in the Registration Statement, the General Disclosure Package and the
    Prospectus, (D) any shares of Common Stock issued pursuant to any non-employee director stock plan or dividend reinvestment plan referred to in the Registration Statement, the General Disclosure Package and the Prospectus, (E) the filing of an
    registration statement on Form S-8 or a successor form thereto with respect to the registration of securities to be offered under any employee benefit or equity incentive plan in existence as of the date hereof and (F) the issuance of up to 5% of the
    outstanding shares of Common Stock in connection with the acquisition of the assets of, or a majority or controlling portion of the equity of, or a joint venture with another entity in connection with the acquisition by the Company or any of its
    subsidiaries of such entity; <i>provided</i> in the case of this clause (F) the transferee of such shares agrees to execute a lock-up agreement substantially in the form of Exhibit A hereto.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">16</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(j)&#160;<i>Reporting Requirements</i>. The Company, during the period when a Prospectus relating to the Securities is (or, but for the exception
    afforded by Rule 172, would be) required to be delivered under the 1933 Act, will file all documents required to be filed with the Commission pursuant to the 1934 Act within the time periods required by the 1934 Act and 1934 Act Regulations.
    Additionally, the Company shall report the use of proceeds from the issuance of the Shares as may be required under Rule 463 under the 1933 Act.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(k)&#160;<i>Issuer Free Writing Prospectuses</i>. The Company agrees that, unless it obtains the prior written consent of the Representatives, it will
    not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &#8220;free writing prospectus,&#8221; or a portion thereof, required to be filed by the Company with the Commission or
    retained by the Company under Rule 433; provided that the Representatives will be deemed to have consented to the Issuer Free Writing Prospectuses listed on <u>Schedule B-2</u> hereto and any &#8220;road show that is a written communication&#8221; within the
    meaning of Rule 433(d)(8)(i) that has been reviewed by the Representatives. The Company represents that it has treated or agrees that it will treat each such free writing prospectus consented to, or deemed consented to, by the Representatives as an
    &#8220;issuer free writing prospectus,&#8221; as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including timely filing with the Commission where required, legending and record
    keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the
    Registration Statement, any preliminary prospectus or the Prospectus or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light
    of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such
    conflict, untrue statement or omission.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(l)&#160;<i>Shelf Renewal</i>. If immediately prior to the third anniversary (the &#8220;Renewal Deadline&#8221;) of the initial effective date of the Registration
    Statement, any of the Securities remain unsold by the Underwriters, the Company will, prior to the Renewal Deadline, file, if it has not already done so and is eligible to do so, a new automatic shelf registration statement relating to the Securities,
    in a form satisfactory to the Representatives. If the Company is not eligible to file an automatic shelf registration statement, the Company will, prior to the Renewal Deadline, if it has not already done so, file a new shelf registration statement
    relating to the Securities, in a form satisfactory to the Representatives, and will use its best efforts to cause such registration statement to be declared effective within 180 days after the Renewal Deadline. The Company will take all other action
    necessary or appropriate to permit the issuance and sale of the Securities to continue as contemplated in the expired registration statement relating to the Securities. References herein to the Registration Statement shall include such new automatic
    shelf registration statement or such new shelf registration statement, as the case may be.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">17</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECTION 4.&#160;<u>Payment of Expenses</u>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(a)&#160;<i>Expenses</i>. The Company will pay or cause to be paid all expenses incident to the performance of their obligations under this Agreement,
    including (i) the preparation, printing and filing of the Registration Statement (including financial statements and exhibits) as originally filed and each amendment thereto, (ii) the preparation, printing and delivery to the Underwriters of copies of
    each preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and any costs associated with electronic delivery of any of the foregoing by the Underwriters to investors, (iii) the
    preparation, issuance and delivery of the certificates or security entitlements for the Securities to the Underwriters, including any stock or other transfer taxes and any stamp or other duties payable upon the sale, issuance or delivery of the
    Securities to the Underwriters, (iv) the fees and disbursements of the Company&#8217;s counsel, accountants and other advisors, (v) the qualification of the Securities under securities laws in accordance with the provisions of Section 3(e) hereof, including
    filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection therewith and in connection with the preparation of the Blue Sky Survey and any supplement thereto, (vi) the fees and expenses of any transfer agent or
    registrar for the Securities, (vii) the costs and expenses of the Company relating to investor presentations on any &#8220;road show&#8221; undertaken in connection with the marketing of the Securities, including without limitation, expenses associated with the
    production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations, travel and lodging expenses of the representatives and officers of the Company and any such consultants, and 50%
    of the cost of aircraft and other transportation chartered in connection with the road show, (viii) the filing fees incident to, and the reasonable fees and disbursements of counsel to the Underwriters in connection with, the review by FINRA of the
    terms of the sale of the Securities (provided, however, that such fees and disbursement of the counsel for the Underwriters pursuant to clauses (v) and (viii) shall not exceed $25,000), (ix) the fees and expenses incurred in connection with the listing
    of the Securities on the New York Stock Exchange and (x) the costs and expenses (including, without limitation, any damages or other amounts payable in connection with legal or contractual liability) associated with the reforming of any contracts for
    sale of the Securities made by the Underwriters caused by a breach of the representation contained in the third sentence of Section 1(a)(ii). It is understood, however, that except as provided in this Section 4, the Underwriters will pay all of their
    own costs and expenses, including the fees of their counsel, stock transfer taxes on resale of any of the Securities by them, and any advertising expenses connection with any offers they may make and that the Underwriters shall be responsible for 50%
    of the cost of aircraft and other transportation chartered in connection with the road show.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(b)&#160;<i>Termination of Agreement</i>. If this Agreement is terminated by the Representatives in accordance with the provisions of Section 5, Section
    9(a)(i) or (iii) or Section 10 hereof, the Company shall reimburse the Underwriters for all of their accountable, out-of-pocket expenses, actually incurred, including the reasonable fees and disbursements of counsel for the Underwriters.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECTION 5.&#160;<u>Conditions of Underwriters&#8217; Obligations</u>. The obligations of the several Underwriters hereunder are subject to the accuracy of the
    representations and warranties of the Company contained herein or in certificates of any officer of the Company or any of its subsidiaries delivered pursuant to the provisions hereof, to the performance by the Company of its covenants and other
    obligations hereunder, and to the following further conditions:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(a)&#160;<i>Effectiveness of Registration Statement</i>. The Registration Statement has become effective and, at the Closing Time, no stop order
    suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no
    proceedings for any of those purposes have been instituted or are pending or, to the Company&#8217;s knowledge, contemplated; and the Company has complied with each request (if any) from the Commission for additional information. The Company shall have paid
    the required Commission filing fees relating to the Securities within the time period required by Rule 456(b)(1)(i) under the 1933 Act Regulations without regard to the proviso therein and otherwise in accordance with Rules 456(b) and 457(r) under the
    1933 Act Regulations and, if applicable, shall have updated the &#8220;Calculation of Registration Fee&#8221; table in accordance with Rule 456(b)(1)(ii) either in a post-effective amendment to the Registration Statement or on the cover page of a prospectus filed
    pursuant to Rule 424(b).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">18</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(b)&#160;<i>Opinion of Counsel for Company</i>. At the Closing Time, the Representatives shall have received the favorable opinion, dated the Closing
    Time, of Porter Hedges LLP, counsel for the Company, and Woodburn and Wedge, Nevada counsel for the Company, in form and substance satisfactory to counsel for the Underwriters, together with signed or reproduced copies of such letter for each of the
    other Underwriters to the effect as counsel to the Underwriters may reasonably request.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(c)&#160;<i>Opinion of Counsel for Underwriters</i>. At the Closing Time, the Representatives shall have received the favorable opinion, dated the
    Closing Time, of Latham &amp; Watkins LLP, counsel for the Underwriters, together with signed or reproduced copies of such letter for each of the other Underwriters. In giving such opinion such counsel may rely, as to all matters governed by the laws
    of jurisdictions other than the law of the State of New York and the federal securities laws of the United States, upon the opinions of counsel satisfactory to the Representatives. Such counsel may also state that, insofar as such opinion involves
    factual matters, they have relied, to the extent they deem proper, upon certificates of officers and other representatives of the Company and its subsidiaries and certificates of public officials.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(d)&#160;<i>Officers&#8217; Certificate</i>. At the Closing Time, there shall not have been, since the date hereof or since the respective dates as of which
    information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and
    its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business, and the Representatives shall have received a certificate of the Chief Executive Officer or the President of the Company and of the chief
    financial or chief accounting officer of the Company, dated the Closing Time, to the effect that (i) there has been no such material adverse change, (ii) the representations and warranties of the Company in this Agreement are true and correct with the
    same force and effect as though expressly made at and as of the Closing Time, (iii) the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied at or prior to the Closing Time, and (iv) no stop
    order suspending the effectiveness of the Registration Statement under the 1933 Act has been issued, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes
    have been instituted or are pending or, to their knowledge, contemplated.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> (e) <font style="font-style: italic;">Chief Financial Officer's Certificate</font>. At the time of the execution of this Agreement, the
    Representatives shall have received from the Chief Financial Officer of the Company, dated such date, in form and substance reasonably satisfactory to the Representatives, giving "management comfort" with respect to certain financial data contained in
    the Registration Statement, the General Disclosure Package and the Prospectus.<br>
  </p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <br>
  </p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(f) <font style="font-style: italic;">Bring-down Chief Financial Officer's Certificate</font>. At the Closing Time, the Representatives shall have
    received from the Chief Financial Officer of the Company, dated the Closing Time, reaffirming the statements made in the certificate furnished pursuant to Section 5(e) hereof.<br>
  </p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <br>
  </p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(g)&#160;<i>Accountant&#8217;s Comfort Letter</i>. At the time of the execution of this Agreement, the Representatives shall have received from Grant Thornton
    LLP a letter, dated such date, in form and substance satisfactory to the Representatives, together with signed or reproduced copies of such letter for each of the other Underwriters containing statements and information of the type ordinarily included
    in accountants&#8217; &#8220;comfort letters&#8221; to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the General Disclosure Package and the Prospectus.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(h)&#160;<i>Bring-down Comfort Letter</i>. At the Closing Time, the Representatives shall have received from Grant Thornton LLP a letter, dated as of the
    Closing Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection [(e)] of this Section, except that the specified date referred to shall be a date not more than three business days prior to the Closing
    Time.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">19</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(i)&#160;<i>Approval of Listing</i>. At the Closing Time, the Securities shall have been approved for listing on the New York Stock Exchange, subject
    only to official notice of issuance.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(j)&#160;<i>No Objection</i>. FINRA has confirmed that it has not raised any objection with respect to the fairness and reasonableness of the
    underwriting terms and arrangements relating to the offering of the Securities.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(k)&#160;<i>Lock-up Agreements</i>. At the date of this Agreement, the Representatives shall have received an agreement substantially in the form of
    Exhibit A hereto signed by the persons listed on <u>Schedule C</u> hereto.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(l)&#160;<i>Maintenance of Rating</i>. Neither the Company nor any of its subsidiaries have any debt securities or preferred stock that are rated by any
    &#8220;nationally recognized statistical rating organization&#8221; (as defined in Section 3(a)(62) of the 1934 Act).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(m)&#160;<i>Conditions to Purchase of Option Securities</i>. In the event that the Underwriters exercise their option provided in Section 2(b) hereof to
    purchase all or any portion of the Option Securities, the representations and warranties of the Company contained herein and the statements in any certificates furnished by the Company and any of its subsidiaries hereunder shall be true and correct as
    of each Date of Delivery and, at the relevant Date of Delivery, the Representatives shall have received:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&#160;<u>Officers&#8217; Certificate</u>. A certificate, dated such Date of Delivery, of the President or a Vice President of the Company and of
    the chief financial or chief accounting officer of the Company confirming that the certificate delivered at the Closing Time pursuant to Section 5(d) hereof remains true and correct as of such Date of Delivery.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&#160;<u>Opinion of Counsel for Company</u>. If requested by the Representatives, the favorable opinion of Porter Hedges LLP, counsel for
    the Company, together with the favorable opinion of Woodburn and Wedge, Nevada counsel for the Company, each in form and substance satisfactory to counsel for the Underwriters, dated such Date of Delivery, relating to the Option Securities to be
    purchased on such Date of Delivery and otherwise to the same effect as the opinion required by Section 5(b) hereof.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)&#160;<u>Opinion of Counsel for Underwriters</u>. If requested by the Representatives, the favorable opinion of Latham and Watkins LLP,
    counsel for the Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinion required by Section 5(c) hereof.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (iv) <u>Bring-down Chief Financial Officer's Certificate</u>. A certificate, dates such Date of Delivery, of the Chief Financial
    Officer of the Company confirming that the certificate delivered at the Closing Time pursuant to Section 5(f) hereof remains true and correct as of such Date of Delivery.<br>
  </p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> <br>
  </p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)&#160;<u>Bring-down Comfort Letter</u>. If requested by the Representatives, a letter from Grant Thornton LLP, in form and substance
    satisfactory to the Representatives and dated such Date of Delivery, substantially in the same form and substance as the letter furnished to the Representatives pursuant to Section 5(h) hereof, except that the &#8220;specified date&#8221; in the letter furnished
    pursuant to this paragraph shall be a date not more than three business days prior to such Date of Delivery.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(n)&#160;<i>Additional Documents</i>. At the Closing Time and at each Date of Delivery (if any) counsel for the Underwriters shall have been furnished
    with such documents and opinions as they may require for the purpose of enabling them to pass upon the issuance and sale of the Securities as herein contemplated, or in order to evidence the accuracy of any of the representations or warranties, or the
    fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Securities as herein contemplated shall be satisfactory in form and substance to the Representatives and
    counsel for the Underwriters.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">20</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(o)&#160;<i>Termination of Agreement</i>. If any condition specified in this Section shall not have been fulfilled when and as required to be fulfilled,
    this Agreement, or, in the case of any condition to the purchase of Option Securities on a Date of Delivery which is after the Closing Time, the obligations of the several Underwriters to purchase the relevant Option Securities, may be terminated by
    the Representatives by notice to the Company at any time at or prior to Closing Time or such Date of Delivery, as the case may be, and such termination shall be without liability of any party to any other party except as provided in Section 4 and
    except that Sections 1, 6, 7, 8, 14, 15, 16 and 17 shall survive any such termination and remain in full force and effect.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECTION 6.&#160;<u>Indemnification</u>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(a)&#160;<i>Indemnification of Underwriters</i>. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates (as such term is
    defined in Rule 501(b) under the 1933 Act (each, an &#8220;Affiliate&#8221;)), its selling agents and each person, if any, who controls any Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act as follows:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&#160;against any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or
    alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, or the omission or alleged omission therefrom of a material
    fact required to be stated therein or necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a material fact included (A) in any preliminary prospectus, any Issuer Free Writing
    Prospectus, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) or (B) in any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering
    of the Securities (&#8220;Marketing Materials&#8221;), including any roadshow or investor presentations made to investors by the Company (whether in person or electronically), or the omission or alleged omission in any preliminary prospectus, Issuer Free Writing
    Prospectus, Prospectus or in any Marketing Materials of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&#160;against any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid
    in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or
    omission; provided that (subject to Section 6(d) below) any such settlement is effected with the written consent of the Company;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)&#160;against any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by the
    Representatives), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue
    statement or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under (i) or (ii) above;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">provided, however, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any
    untrue statement or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the
    Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter Information.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">21</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#160;<i>Indemnification of Company, Directors and Officers</i>. Each Underwriter severally agrees to indemnify and hold harmless the Company, its
    directors, each of its officers who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act, against any and all loss, liability, claim, damage
    and expense described in the indemnity contained in subsection (a) of this Section, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendment
    thereto), including any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter Information.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#160;<i>Actions against Parties; Notification</i>. Each indemnified party shall give notice as promptly as reasonably practicable to each
    indemnifying party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party shall not relieve such indemnifying party from any liability hereunder to the extent it is not
    materially prejudiced as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement. In the case of parties indemnified pursuant to Section 6(a) above, counsel to
    the indemnified parties shall be selected by the Representatives, and, in the case of parties indemnified pursuant to Section 6(b) above, counsel to the indemnified parties shall be selected by the Company. An indemnifying party may participate at its
    own expense in the defense of any such action; provided, however, that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to the indemnified party. In no event shall the indemnifying parties
    be liable for fees and expenses of more than one counsel (in addition to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action or separate but similar or related actions in the same
    jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any
    litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever in respect of which indemnification or contribution could be sought under this Section 6 or Section 7 hereof (whether or
    not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation,
    proceeding or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#160;<i>Settlement without Consent if Failure to Reimburse</i>. If at any time an indemnified party shall have requested an indemnifying party to
    reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section 6(a)(ii) effected without its written consent if (i) such settlement is
    entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and
    (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECTION 7.&#160;<u>Contribution</u>. If the indemnification provided for in Section 6 hereof is for any reason unavailable to or insufficient to hold
    harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses
    incurred by such indemnified party, as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Securities pursuant
    to this Agreement or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the
    Company, on the one hand, and of the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well as any other relevant equitable considerations.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">22</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the
    Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities pursuant to this Agreement (before deducting expenses) received by the Company, on the one
    hand, and the total underwriting discount received by the Underwriters, on the other hand, in each case as set forth on the cover of the Prospectus, bear to the aggregate initial public offering price of the Securities as set forth on the cover of the
    Prospectus.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other
    things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#8217; relative intent, knowledge,
    access to information and opportunity to correct or prevent such statement or omission.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 7 were determined by pro
    rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to above in this Section 7. The aggregate amount of losses,
    liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section 7 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in investigating, preparing or
    defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or omission or alleged omission.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the provisions of this Section 7, no Underwriter shall be required to contribute any amount in excess of the underwriting
    commissions received by such Underwriter in connection with the Shares underwritten by it and distributed to the public.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution from any
    person who was not guilty of such fraudulent misrepresentation.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this Section 7, each person, if any, who controls an Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of
    the 1934 Act and each Underwriter&#8217;s Affiliates and selling agents shall have the same rights to contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if
    any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the same rights to contribution as the Company. The Underwriters&#8217; respective obligations to contribute pursuant to this Section 7
    are several in proportion to the number of Initial Securities set forth opposite their respective names in <u>Schedule A</u> hereto and not joint.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECTION 8.&#160;<u>Representations, Warranties and Agreements to Survive</u>. All representations, warranties and agreements contained in this Agreement
    or in certificates of officers of the Company or any of its subsidiaries submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or
    selling agents, any person controlling any Underwriter, its officers or directors, any person controlling the Company and (ii) delivery of and payment for the Securities.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">23</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECTION 9.&#160;<u>Termination of Agreement</u>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(a)&#160;<i>Termination</i>. The Representatives may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing Time (i)
    if there has been, in the judgment of the Representatives, since the time of execution of this Agreement or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any
    material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business, or
    (ii) if there has occurred any material adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development
    involving a prospective change in national or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of the Representatives, impracticable or inadvisable to proceed with the
    completion of the offering or to enforce contracts for the sale of the Securities, or (iii) if trading in any securities of the Company has been suspended or materially limited by the Commission or the New York Stock Exchange, or (iv) if trading
    generally on the NYSE MKT or the New York Stock Exchange or in the Nasdaq Global Select Market has been suspended or materially limited, or minimum or maximum prices for trading have been fixed, or maximum ranges for prices have been required, by any
    of said exchanges or by order of the Commission, FINRA or any other governmental authority, or (v) a material disruption has occurred in commercial banking or securities settlement or clearance services in the United States or with respect to
    Clearstream or Euroclear systems in Europe, or (vi) if a banking moratorium has been declared by either Federal or New York authorities.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(b)&#160;<i>Liabilities</i>. If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any party to any
    other party except as provided in Section 4 hereof, and provided further that Sections 1, 6, 7, 8, 14, 15, 16 and 17 shall survive such termination and remain in full force and effect.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECTION 10. <u>Default by One or More of the Underwriters</u>. If one or more of the Underwriters shall fail at the Closing Time or a Date of
    Delivery to purchase the Securities which it or they are obligated to purchase under this Agreement (the &#8220;Defaulted Securities&#8221;), the Representatives shall have the right, within 24 hours thereafter, to make arrangements for one or more of the
    non-defaulting Underwriters, or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and upon the terms herein set forth; if, however, the Representatives shall not have
    completed such arrangements within such 24-hour period, then:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(i)&#160;if the number of Defaulted Securities does not exceed 10% of the number of Securities to be purchased on such date, each of the non-defaulting
    Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that their respective underwriting obligations hereunder bear to the underwriting obligations of all non-defaulting Underwriters, or</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(ii)&#160;if the number of Defaulted Securities exceeds 10% of the number of Securities to be purchased on such date, this Agreement or, with respect to
    any Date of Delivery which occurs after the Closing Time, the obligation of the Underwriters to purchase, and the Company to sell, the Option Securities to be purchased and sold on such Date of Delivery shall terminate without liability on the part of
    any non-defaulting Underwriter.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">24</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No action taken pursuant to this Section shall relieve any defaulting Underwriter from liability in respect of its default.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of any such default which does not result in a termination of this Agreement or, in the case of a Date of Delivery which is after the
    Closing Time, which does not result in a termination of the obligation of the Underwriters to purchase and the Company to sell the relevant Option Securities, as the case may be, either the (i) Representatives or (ii) the Company shall have the right
    to postpone Closing Time or the relevant Date of Delivery, as the case may be, for a period not exceeding seven days in order to effect any required changes in the Registration Statement, the General Disclosure Package or the Prospectus or in any other
    documents or arrangements. As used herein, the term &#8220;Underwriter&#8221; includes any person substituted for an Underwriter under this Section 10.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECTION 11. <u>Notices</u>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if
    mailed or transmitted by any standard form of telecommunication. Notices to the Underwriters shall be directed to BofA at One Bryant Park, New York, New York 10036, attention of Syndicate Department (email: dg.ecm_execution_services@bofa.com), with a
    copy to ECM Legal (email: <u>dg.ecm_legal@bofa.com</u>) and to J.P. Morgan at 383 Madison Avenue, New York, New York 10179 (fax: (212) 622-8358), attention of Equity Syndicate Desk; notices to the Company shall be directed to it at U.S. Physical
    Therapy, Inc., 1300 West Sam Houston Parkway South, Suite 300, Houston, Texas 77042, attention of Chief Financial Officer (email: chendrickson@usph.com).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECTION 12. <u>No Advisory or Fiduciary Relationship</u>. The Company acknowledges and agrees that (a) the purchase and sale of the Securities
    pursuant to this Agreement, including the determination of the initial public offering price of the Securities and any related discounts and commissions, is an arm&#8217;s-length commercial transaction between the Company, on the one hand, and the several
    Underwriters, on the other hand, and does not constitute a recommendation, investment advice, or solicitation of any action by the Underwriters, (b) in connection with the offering of the Securities and the process leading thereto, each Underwriter is
    and has been acting solely as a principal and is not the agent or fiduciary of the Company or any of its subsidiaries, or its respective stockholders, creditors, employees or any other party, (c) no Underwriter has assumed or will assume an advisory or
    fiduciary responsibility in favor of the Company with respect to the offering of the Securities or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company or any of its subsidiaries on
    other matters) and no Underwriter has any obligation to the Company with respect to the offering of the Securities except the obligations expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged in a
    broad range of transactions that involve interests that differ from those of the Company, and (e) the Underwriters have not provided any legal, accounting, regulatory, investment or tax advice with respect to the offering of the Securities and the
    Company has consulted its own legal, accounting, financial, regulatory and tax advisors to the extent it deemed appropriate, and (f) none of the activities of the Underwriters in connection with the transactions contemplated herein constitutes a
    recommendation, investment advice or solicitation of any action by the Underwriters with respect to any entity or natural person.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECTION 13. <u>Recognition of the U.S. Special Resolution Regimes</u>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(a)&#160;In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer
    from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such
    interest and obligation, were governed by the laws of the United States or a state of the United States.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">25</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(b)&#160;In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a
    U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime
    if this Agreement were governed by the laws of the United States or a state of the United States.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">For purposes of this Section 13, a &#8220;BHC Act Affiliate&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance
    with, 12 U.S.C. &#167; 1841(k). &#8220;Covered Entity&#8221; means any of the following: (i) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in
    accordance with, 12 C.F.R. &#167; 47.3(b); or (iii) a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). <b>&#8220;</b>Default Right&#8221; has the meaning assigned to that term in, and shall be interpreted in
    accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. &#8220;U.S. Special Resolution Regime&#8221; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform
    and Consumer Protection Act and the regulations promulgated thereunder.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECTION 14. <u>Parties</u>. This Agreement shall each inure to the benefit of and be binding upon the Underwriters, the Company and their
    respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other than the Underwriters, the Company and their respective successors and the controlling persons and
    officers and directors referred to in Sections 6 and 7 and their heirs and legal representatives, any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement and all conditions
    and provisions hereof are intended to be for the sole and exclusive benefit of the Underwriters, the Company and their respective successors, and said controlling persons and officers and directors and their heirs and legal representatives, and for the
    benefit of no other person, firm or corporation. No purchaser of Securities from any Underwriter shall be deemed to be a successor by reason merely of such purchase.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECTION 15. <u>Trial by Jury</u>. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and
    affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions
    contemplated hereby.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECTION 16. <u>GOVERNING LAW</u>. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED
    BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECTION 17. <u>Consent to Jurisdiction; Waiver of Immunity</u>. Any legal suit, action or proceeding arising out of or based upon this Agreement or
    the transactions contemplated hereby (&#8220;Related Proceedings&#8221;) shall be instituted in (i) the federal courts of the United States of America located in the City and County of New York, Borough of Manhattan or (ii) the courts of the State of New York
    located in the City and County of New York, Borough of Manhattan (collectively, the &#8220;Specified Courts&#8221;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of
    any such court (a &#8220;Related Judgment&#8221;), as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party&#8217;s address set forth above shall be
    effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and
    irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">26</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECTION 18. <u>TIME</u>. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW
    YORK CITY TIME.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECTION 19. <u>Counterparts and Electronic Signatures</u>. This Agreement may be executed in any number of counterparts, each of which shall be
    deemed to be an original, but all such counterparts shall together constitute one and the same Agreement. Electronic signatures complying with the New York Electronic Signatures and Records Act (N.Y. State Tech. &#167;&#167; 301-309), as amended from time to
    time, or other applicable law will be deemed original signatures for purposes of this Agreement. Transmission by telecopy, electronic mail or other transmission method of an executed counterpart of this Agreement will constitute due and sufficient
    delivery of such counterpart.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECTION 20. <u>Effect of Headings</u>. The Section headings herein are for convenience only and shall not affect the construction hereof.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">27</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing is in accordance with your understanding of our agreement, please sign and return to the Company a counterpart hereof, whereupon
    this instrument, along with all counterparts, will become a binding agreement among the Underwriters and the Company in accordance with its terms.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

      <tr style="vertical-align: top">
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">Very truly yours,</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td colspan="2"><font style="font-family: Times New Roman, Times, Serif">U.S. PHYSICAL THERAPY, INC.</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="width: 50%"></td>
        <td style="width: 3%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</font></td>
        <td style="width: 37%; border-bottom: Black 1pt solid">/s/ Richard Binstein<br>
        </td>
        <td style="width: 10%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">Title: Executive Vice President and General Counsel<br>
          </font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONFIRMED AND ACCEPTED,<br>
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;as of the date first above written:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-indent: -82.35pt">BOFA SECURITIES, INC.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-indent: -82.35pt">&#160;&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="text-align: justify; width: 3%"><font style="font-family: Times New Roman, Times, Serif">By</font></td>
        <td style="width: 47%; border-bottom: 1pt solid Black; text-align: center;"><font style="font-family: Times New Roman,Times,serif;">/s/ Sumit Mukherjee<br>
          </font></td>
        <td style="width: 50%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: justify">
        <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif">Authorized Signatory</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-indent: -82.35pt">J.P. MORGAN SECURITIES LLC</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-indent: -82.35pt">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="text-align: justify; width: 3%"><font style="font-family: Times New Roman, Times, Serif">By</font></td>
        <td style="width: 47%; border-bottom: 1pt solid Black; text-align: center;"><font style="font-family: Times New Roman,Times,serif;">/s/ Benjamin Burdett<br>
          </font></td>
        <td style="width: 50%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: justify">
        <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif">Authorized Signatory</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For themselves and as Representatives of the other Underwriters named in <u>Schedule A</u> hereto.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">28</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <!--PROfilePageNumberReset%Num%1%Sch A -%%-->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE A</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The initial public offering price per share for the Securities shall be $90.00.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The purchase price per share for the Securities to be paid by the several Underwriters shall be $85.50, being an amount equal to the initial public offering price set forth above less
    $4.50 per share, subject to adjustment in accordance with Section 2(b) for dividends or distributions declared by the Company and payable on the Initial Securities but not payable on the Option Securities.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: bottom">
        <td style="width: 85%">Name of Underwriter</td>
        <td style="width: 15%; text-align: center">Number of<br>
          <u>Initial Securities</u></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>BofA Securities, Inc. </td>
        <td style="text-align: center;">708,333<br>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td>J.P. Morgan Securities LLC </td>
        <td style="text-align: center;">500,000<br>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1">Jefferies LLC<br>
        </td>
        <td rowspan="1" style="text-align: center;">291,667<br>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1">Regions Securities LLC<br>
        </td>
        <td rowspan="1" style="text-align: center;">66,667<br>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1">
          <div>Barrington Research Associates, Inc.<br>
          </div>
        </td>
        <td rowspan="1" style="text-align: center;">50,000<br>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1">CJS Securities, Inc.<br>
        </td>
        <td rowspan="1" style="text-align: center;">50,000</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 0.25in; padding-bottom: 2.5pt">Total </td>
        <td style="padding-bottom: 2.5pt; border-bottom: Black 2.5pt double">
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1,666,667<br>
          </p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">Sch A -1</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <!--PROfilePageNumberReset%Num%1%Sch B -%%-->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE B-1</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><u>Pricing Terms</u></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&#160;The Company is selling 1,666,667 shares of Common Stock.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&#160;The Company has granted an option to the Underwriters, severally and not jointly, to purchase up to an additional 250,000 shares of Common Stock.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&#160;The initial public offering price per share for the Securities shall be $90.00.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">Sch B -1</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE B-2</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><u>Free Writing Prospectuses</u></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">Sch B -2</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <!--PROfilePageNumberReset%Num%1%Sch C -%%-->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE C</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><u>List of Persons and Entities Subject to Lock-up</u></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chris J. Reading&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Edward L. Kuntz&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Bernard A. Harris, Jr.&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kathleen A. Gilmartin&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Anne Motsenbocker&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reginald E. Swanson&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Clayton K. Trier&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nancy J. Ham&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Richard S. Binstein&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carey P. Hendrickson&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Graham D. Reeve&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eric J. Williams&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">Sch C -1</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <!--PROfilePageNumberReset%Num%1%A-%%-->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Form of lock-up from directors, officers or other stockholders pursuant to Section 5(k)</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit A</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[ <font style="font-family: Times New Roman, Times, Serif">&#9679;</font> ], 2023</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BofA Securities, Inc.&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">J.P. Morgan Securities LLC<br>
    &#160;&#160;&#160;&#160;&#160;as Representatives of the several<br>
    &#160;&#160;&#160;&#160;&#160;Underwriters to be named in the<br>
    &#160;&#160;&#160;&#160;&#160;within-mentioned Underwriting Agreement<br>
    &#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>c/o BofA Securities, Inc.</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">One Bryant Park<br>
    New York, New York 10036</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>c/o J.P. Morgan Securities LLC</b>&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">383 Madison Avenue&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10179</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Re: <u>Proposed Public Offering by U.S. Physical Therapy, Inc.</u></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Sirs:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned, a stockholder and an officer and/or director of U.S. Physical Therapy, Inc., a Nevada corporation (the &#8220;Company&#8221;), understands
    that BofA Securities, Inc. (&#8220;BofA&#8221;) and J.P. Morgan Securities LLC (&#8220;J.P. Morgan&#8221;) propose to enter into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with the Company providing for the public offering of shares of the Company&#8217;s common
    stock, par value $0.01 per share (the &#8220;Common Stock&#8221;). In recognition of the benefit that such an offering will confer upon the undersigned as a stockholder and an officer and/or director of the Company, and for other good and valuable consideration,
    the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each underwriter to be named in the Underwriting Agreement that, during the period beginning on the date hereof and ending on the date that is 90 days from the
    date of the Underwriting Agreement (subject to extensions as discussed below), the undersigned will not, without the prior written consent of BofA and J.P. Morgan, (i) directly or indirectly, offer, pledge, lend, sell, contract to sell, sell any option
    or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares of the Company&#8217;s Common Stock or any securities convertible into or exercisable or
    exchangeable for Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (collectively, the &#8220;Lock-Up Securities&#8221;), or exercise any right with
    respect to the registration of any of the Lock-up Securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act of 1933, as amended, (ii) enter into any swap or any other agreement or any
    transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether any such swap or transaction is to be settled by delivery of Common Stock or other securities, in cash or
    otherwise, or (iii) publicly disclose the intention to do any of the foregoing. The undersigned acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transactions or arrangements (including, without
    limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could
    reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any Lock-Up Securities,
    whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of Lock-Up Securities, in cash or otherwise.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">A-1</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer the Lock-Up Securities without the prior written
    consent of BofA and J.P. Morgan, provided that (1) BofA and J.P. Morgan receive a signed lock-up agreement for the balance of the lockup period from each donee, trustee, distributee, or transferee, as the case may be, (2) any such transfer shall not
    involve a disposition for value, (3) such transfers are not required to be reported with the Securities and Exchange Commission on Form 4 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and (4) the undersigned does not
    otherwise voluntarily effect any public filing or report regarding such transfers:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <table width="100%" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in">(i)</td>
        <td style="text-align: justify">as a <i>bona fide</i> gift or gifts; or</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>
  <table width="100%" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in">(ii)</td>
        <td style="text-align: justify">to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this lock-up agreement, &#8220;immediate family&#8221; shall mean any relationship by blood,
          marriage, domestic partnership or adoption, not more remote than first cousin);</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>
  <table width="100%" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in">(iii)</td>
        <td style="text-align: justify">as a distribution to limited partners or stockholders of the undersigned;</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>
  <table width="100%" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in">(iv)</td>
        <td style="text-align: justify">to any partnership, limited liability company or other entity of which the undersigned and the immediate family of the undersigned are the legal and beneficial owner of all of the outstanding equity securities or
          similar interests;</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>
  <table width="100%" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in">(v)</td>
        <td style="text-align: justify">to any immediate family member or any investment fund or other entity controlled or managed by the undersigned;</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>
  <table width="100%" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in">(vi)</td>
        <td style="text-align: justify">if the undersigned is a corporation, partnership, limited liability company, trust or other business entity, (A) to another corporation, partnership, limited liability company, trust or other business entity that is
          an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the
          undersigned or affiliates of the undersigned (including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B) as
          part of a distribution, transfer or disposition by the undersigned to its stockholders, limited partners, general partners, limited liability company members or other equityholders or to the estate of any such stockholders, limited partners,
          general partners, limited liability company members or equityholders;</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>
  <table width="100%" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in">(vii)</td>
        <td style="text-align: justify">by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement;</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>
  <table width="100%" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in">(viii)</td>
        <td style="text-align: justify">the establishment of a trading plan that meets the requirements of Rule 10b5-1(c) under the Exchange Act (a &#8220;Trading Plan&#8221;); provided, however, that (a) no transfer occur under such plan during the Lock-up Period and
          (b) no public announcement or filing under the Exchange Act shall be required or voluntarily made by or on behalf of the undersigned or the Company regarding the establishment of such plan during the Lock-Up Period;</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>
  <table width="100%" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in">(ix)</td>
        <td style="text-align: justify">to the Underwriters pursuant to the Underwriting Agreement; or</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">A-2</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>
  <table width="100%" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in">(x)</td>
        <td style="text-align: justify">(A) transfers to the Company in connection with the vesting, settlement, or exercise of restricted stock units, options, warrants or other rights to purchase shares of Common Stock (including, in each case, by way of
          &#8220;net&#8221; or &#8220;cashless&#8221; exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting, settlement, or exercise of such restricted stock units, options, warrants or rights, or (B) transfers
          necessary (including transfers on the open market) to generate such amount of cash needed for the payment of taxes, including estimated taxes, due as a result of the vesting or settlement of restricted stock units whether by means of a &#8220;net
          settlement&#8221; or otherwise, and in all such cases described in subclauses (A) and (B), provided that any such shares of Common Stock received upon such exercise, vesting or settlement shall be subject to the terms of this agreement, and provided
          further that any such restricted stock units, options, warrants or rights are held by the undersigned pursuant to an agreement or equity awards granted under a stock incentive plan or other equity award plan, each such agreement or plan which is
          described in the Prospectus; <i>provided</i> that (1) any filing under Section 16 of the Exchange Act made during the Lock-Up Period shall clearly indicate in the footnotes thereto that (i) the filing relates to the circumstances described in
          the applicable clause and (ii) to the extent applicable, the underlying shares of Common Stock continue to be subject to the restrictions on transfer set forth in this lock-up agreement and (2) the undersigned does not otherwise voluntarily
          effect any other public filings or reports regarding such exercise during the Lock-Up Period.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, the undersigned may sell shares of Common Stock of the Company purchased by the undersigned on the open market following the Public
    Offering if and only if (i) such sales are not required to be reported in any public report or filing with the Securities and Exchange Commission, or otherwise and (ii) the undersigned does not otherwise voluntarily effect any public filing or report
    regarding such sales.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned acknowledges and agrees that the underwriters have not provided any recommendation or investment advice nor have the underwriters
    solicited any action from the undersigned with respect to the offering of the securities and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#8217;s transfer agent and registrar against the
    transfer of the Lock-Up Securities except in compliance with the foregoing restrictions.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
  <table cellspacing="0" cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">

      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td colspan="2">Very truly yours,</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 50%">&#160;</td>
        <td style="width: 9%">&#160;</td>
        <td style="width: 31%">&#160;</td>
        <td style="width: 10%">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td>Signature:</td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>

  </table>
  <p style="margin: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 50%">&#160;</td>
        <td style="width: 10%">Print Name:</td>
        <td style="width: 30%; border-bottom: Black 1pt solid">&#160;</td>
        <td style="width: 10%">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">A-3</font>&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ny20009213x3_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">
        <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">Exhibit 5.1</div>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div> <br>
    </div>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">May 24, 2023</div>
    </div>
    <div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">U.S. Physical Therapy, Inc.</div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1300 West Sam Houston Parkway South, Suite 300</div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Houston, TX 77042</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ladies and Gentlemen:</div>
      <div><br>
      </div>
    </div>
    <div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have acted as special Nevada counsel to U.S. Physical Therapy, Inc., a Nevada corporation (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Company</u></font>&#8221;), in connection with the offer and sale by the Company of 1,666,667 shares (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Underwritten
            Shares</u></font>&#8221;) of common stock of the Company, $0.01 par value per share (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Common Stock</u></font>&#8221;), and an additional 250,000 shares of the Common Stock
        pursuant to the exercise of the over-allotment option (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Option Shares</u></font>,&#8221; and together with the Underwritten Shares, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Shares</u></font>&#8221;).&#160; The offer and sale of the Shares have been registered pursuant to a Registration Statement on Form S-3 (Registration No. 333-272147) filed by the Company with the Securities
        and Exchange Commission (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Commission</u></font>&#8221;), under the Securities Act of 1933, as amended (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Securities Act</u></font>&#8221;) (as so filed and as amended, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Registration Statement</u></font>&#8221;), including a base prospectus dated May 23, 2023
        (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Base Prospectus</u></font>&#8221;), as supplemented by a Final Prospectus Supplement dated May 24, 2023 relating to the Shares (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Prospectus Supplement</u></font>,&#8221; and together with the Base Prospectus, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Disclosure Package</u></font>&#8221;). The
        Company has entered into an Underwriting Agreement dated as of May 24, 2023, among the Company and BofA Securities, Inc. and J.P. Morgan Securities LLC, as representatives of the Underwriters listed on Schedule A thereto (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Underwriting Agreement</u></font>&#8221;), relating to the sale of the Shares.&#160; Capitalized terms not defined herein shall have such meaning as set forth in the Underwriting
        Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In connection with this opinion, we have examined originals or copies, certified, or otherwise identified to our satisfaction, of:</div>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za771b64bcd64473b90a7ed25883a28a8">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Articles of Incorporation of the Company, as filed with the Nevada Secretary of State on April 1, 1992, as amended by a Certificate of Amendment to Articles of
                Incorporation, as filed with the Nevada Secretary of State on May 31, 2001 (as so amended, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Articles of Incorporation</u></font>&#8221;);</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9cb3be5a587e4d83b2365aa7c1615084">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Bylaws of the Company, dated as of October 11, 1990, as ratified by the Board of Directors of the Company on March 7, 2019, and certified to us to be currently in
                effect (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Bylaws</u></font>,&#8221; and together with the Articles of Incorporation, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Governing Documents</u></font>&#8221;);</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">U.S. Physical Therapy, Inc.</div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">May 24, 2023</div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Page 2</div>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z796d1e849373415abf4f47583d2fc65d">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A Certificate of Good Standing for the Company issued by the Nevada Secretary of State on May 23, 2023</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z39a53063352c4a0fba1d6dd3045b5ff3">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iv)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Registration Statement;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7fd4b423b78d492c882cf2c2227c4c46">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(v)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Base Prospectus;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z863ca0ad06654e6d94bedd3048d1c141">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(vi)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Preliminary Prospectus;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze284148e1c6442d988c4ecbeea213c95">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(vii)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Final Prospectus;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8eb9e65a50124a14925b95dbf0b16920">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(viii)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">resolutions adopted by the Board of Directors of the Company (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Board of Directors</u></font>&#8221;)

                dated May 2, 2023, authorizing and approving the Registration Statement, the issuance and sale of the securities described in the Registration Statement;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd62b250bc9f84558bfb5b572a54de610">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ix)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Resolutions of the Board of Directors adopted as of May 2, 2023, authorizing and approving the Underwriting Agreement, the Preliminary Prospectus Supplement, the
                issuance and sale of the securities described in the Preliminary Prospectus Supplement, and designating the Pricing Committee;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zae6f34b67c0b495db344ab88c32380ce">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(x)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Resolutions of the Pricing Committee of the Board of Directors, dated May 24, 2023, approving certain pricing terms of the Shares, and matters related thereto; and</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6395a5cb2a134426885fa6e43f4b28b1">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(xi)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A certificate, dated May 24, 2023, from an Officer of the Company as to certain factual matters, including the Governing Documents, the resolutions referenced in
                items (viii) through (x), and the incumbency of the officers of the Company (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Officer&#8217;s Certificate</u></font>&#8221;).</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition to the foregoing, we have examined such other instruments, documents and records that we deemed relevant and necessary for
      the basis of our opinion hereinafter expressed.&#160; We have assumed the authenticity of all records, documents and instruments submitted to us as originals, the genuineness of all signatures, the legal capacity of natural persons and the conformity to
      the originals of all records, documents and instruments submitted to us as copies.</div>
    <div><br>
    </div>
    <div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In rendering the opinions contained herein, we have, with your permission, made the following assumptions: (i) all documents submitted
        to or reviewed by us, including all amendments and supplements thereto, are accurate and complete and, if not originals, are true, correct, and complete copies of the originals; (ii) the signatures on each of such documents by the parties thereto
        are genuine; (iii) each individual who signed such documents had the legal capacity to do so; (iv) all persons who signed such documents on behalf of a business entity were duly authorized to do so; (v) all statements in certificates of public
        officials and officers of the Company that we reviewed were and are accurate, and (vi) all representations made by the Company as to matters of fact in the documents that we reviewed were and are accurate. We have assumed that there are no
        amendments, modifications, or supplements to such documents other than those amendments, modifications, and supplements that are known to us.</div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This opinion is limited to the Nevada Revised Statutes, and we disclaim any opinion as to the laws of any other jurisdiction.&#160; We
      further disclaim any opinion as to any other statute, rule, regulation, ordinance, order or other promulgation of any other jurisdiction or any regional or local governmental body or as to any related judicial or administrative opinion.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">U.S. Physical Therapy, Inc.</div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">May 24, 2023</div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Page 3<br>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based upon the foregoing and our examination of such questions of law as we have deemed necessary or appropriate for the purpose of this
      opinion, it is our opinion that upon receipt of consideration therefor, the Shares will be validly issued, fully paid and nonassessable.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This opinion is rendered to you in connection with the Registration Statement and is not to be relied upon for any other purpose. We
      disclaim any obligation to advise you of any change of law that occurs, or any facts of which we may become aware, after the date of this opinion.</div>
    <div><br>
    </div>
    <div>
      <div style="text-align: justify;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">This opinion is based upon our knowledge of the law and facts relevant to the transactions herein referenced as of the date
          hereof. We assume no duty to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or to reflect any changes in any law that may hereafter occur or become effective.</font></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We hereby consent to the filing of this opinion as Exhibit
        5.1 to the Company&#8217;s Current Report on Form 8-K. In giving this consent, we do not thereby admit that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the
        Securities and Exchange Commission.</font></div>
    <div style="text-align: justify;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z183836d36fb346a19dda0234a7b46cb4">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">WOODBURN AND WEDGE</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
          </td>
          <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Shawn G. Pearson<br>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 47%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shawn G. Pearson</div>
          </td>
        </tr>

    </table>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>ny20009213x3_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">
      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">Exhibit 99.1</div>
    <div>
      <div><br>
      </div>
      <div style="text-align: left;"><img width="234" height="111" src="ny20009213x3_ex99-1image01.jpg"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CONTACT:</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">U.S. Physical Therapy, Inc.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carey Hendrickson, Chief Financial Officer</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Email: chendrickson@usph.com</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Chris Reading, Chief Executive Officer</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(713) 297-7000</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Three Part Advisors</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Joe Noyons</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(817) 778-8424</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold;">U.S. Physical Therapy Announces $150 Million</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold;">Underwritten Public Offering of Common Stock</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">HOUSTON, May 23, 2023</font> &#8211; U.S. Physical Therapy, Inc.
      (NYSE: USPH) (&#8220;U.S. Physical Therapy&#8221; or the &#8220;Company&#8221;) today announced that it has commenced an underwritten public offering of $150,000,000 of shares of common stock. The Company has granted the underwriters an option to purchase up to an
      additional $22,500,000 of shares of common stock from the Company.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">U.S. Physical Therapy intends to use the net proceeds of this offering for repayment of a portion of its indebtedness outstanding under its revolving
      credit facility, and for general corporate purposes, including future acquisitions and other capital expenditures, as well as funding working capital and paying dividends.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">BofA Securities and J.P. Morgan are acting as joint lead bookrunners for the offering, and Jefferies is acting as bookrunner. The offering is subject to
      market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The offering is being made pursuant to an effective shelf registration statement, which has been filed with the Securities and Exchange Commission (the
      &#8220;SEC&#8221;) and became effective May 23, 2023. The offering will be made only by means of a preliminary prospectus supplement and the accompanying base prospectus, copies of which may be obtained on the SEC&#8217;s website at<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;<u>www.sec.gov</u></font> or from BofA Securities, Attn: Prospectus
      Department, NC1-022-02-25, 201 North Tryon, Charlotte, NC 28255-0001, or by email at dg.prospectus_requests@bofa.com and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at
      prospectus-eq_fi@jpmchase.com.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release is neither an offer to sell nor a solicitation of an offer to buy any securities being offered, nor shall there be any sale of any such
      securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><u>About U.S. Physical Therapy</u></div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Founded in 1990, U.S. Physical Therapy operates 649 outpatient physical therapy clinics in 40 states. The Company's clinics provide preventative and
      post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages 34
      physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The Company also has an industrial injury prevention business which provides onsite services for clients&#8217; employees including injury prevention and
      rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><u>Forward-Looking Statements</u></div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release contains statements that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of
      1934, as amended. These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as
      &#8220;believes&#8221;, &#8220;expects&#8221;, &#8220;intends&#8221;, &#8220;plans&#8221;, &#8220;appear&#8221;, &#8220;should&#8221; and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we expect. Included among such statements may be those relating to new
      clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements
      as a result of certain risks, uncertainties, and factors. Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. For additional information regarding these and other
      risks and uncertainties, that could cause actual results to differ materially from those contained in our forward-looking statements, please refer to &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with
      the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 28, 2023 and any risk factors contained in subsequent quarterly and annual reports we file with the SEC. Our forward-looking statements represent our estimates and assumptions only as of the
      date of this report. Except as required by law, we are under no obligation to update any forward-looking statement as a result of new information, future events, or otherwise, except as required by law.
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>ny20009213x3_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">
      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">Exhibit 99.2</div>
    <div><br>
    </div>
    <div>
      <div style="text-align: left;"><img width="234" height="111" src="ny20009213x3_ex99-1image01.jpg"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CONTACT:</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">U.S. Physical Therapy, Inc.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carey Hendrickson, Chief Financial Officer</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Email: chendrickson@usph.com</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Chris Reading, Chief Executive Officer</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(713) 297-7000</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Three Part Advisors</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Joe Noyons</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(817) 778-8424</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold;">U.S. Physical Therapy Announces Pricing of $150 Million</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold;">Underwritten Public Offering of Common Stock</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">HOUSTON, TX, May 24, 2023</font> &#8211; U.S. Physical Therapy,
      Inc. (NYSE: USPH) (&#8220;U.S. Physical Therapy&#8221; or the &#8220;Company&#8221;) today announced that it has priced an underwritten public offering of 1,666,667 shares of common stock at a price to the public of $90.00 per share of common stock. The underwriters have an
      option for 30 days to purchase up to an additional 250,000 shares of common stock from the Company. The offering is expected to close on May 30, 2023, subject to customary closing conditions.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The gross proceeds from the offering to U.S. Physical Therapy are expected to be approximately $150 million, before deducting underwriting discounts and
      commissions and offering expenses. U.S. Physical Therapy intends to use the net proceeds of this offering for repayment of a portion of its indebtedness outstanding under its revolving credit facility, and for general corporate purposes, including
      future acquisitions and other capital expenditures, as well as funding working capital and paying dividends.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">BofA Securities and J.P. Morgan are acting as joint lead bookrunners, Jefferies is acting as bookrunner, and Regions Securities LLC, Barrington Research
      and CJS Securities are acting as co-managers for the offering.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The offering is being made pursuant to an effective shelf registration statement, which was filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;)
      and became automatically effective on May 23, 2023. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and the accompanying
      prospectus will be filed with the SEC, copies of which may be obtained on the SEC&#8217;s website at <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">www.sec.gov</font> or from BofA Securities, Attn:
      Prospectus Department, NC1-022-02-25, 201 North Tryon, Charlotte, NC 28255-0001, or by email at dg.prospectus_requests@bofa.com and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by
      email at prospectus-eq_fi@jpmchase.com.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release is neither an offer to sell nor a solicitation of an offer to buy any securities being offered, nor shall there be any sale of any such
      securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><u>About U.S. Physical Therapy</u></div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Founded in 1990, U.S. Physical Therapy operates 649 outpatient physical therapy clinics in 40 states. The Company&#8217;s clinics provide preventative and
      post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages 34
      physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The Company also has an industrial injury prevention business which provides onsite services for clients&#8217; employees including injury prevention and
      rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><u>Forward-Looking Statements</u></div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release contains statements that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of
      1934, as amended. These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as
      &#8220;believes&#8221;, &#8220;expects&#8221;, &#8220;intends&#8221;, &#8220;plans&#8221;, &#8220;appear&#8221;, &#8220;should&#8221; and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we expect. Included among such statements may be those relating to new
      clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements
      as a result of certain risks, uncertainties, and factors. Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. For additional information regarding these and other
      risks and uncertainties, that could cause actual results to differ materially from those contained in our forward-looking statements, please refer to &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with
      the SEC on February 28, 2023 and any risk factors contained in subsequent quarterly and annual reports we file with the SEC. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required
      by law, we are under no obligation to update any forward-looking statement as a result of new information, future events, or otherwise, except as required by law.
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>usph-20230523.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.2.5148 Broadridge-->
<xs:schema targetNamespace="http://usph.com/20230523" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:usph="http://usph.com/20230523" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="usph-20230523_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="usph-20230523_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://usph.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>usph-20230523_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.2.5148 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>usph-20230523_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.2.5148 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://usph.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="usph-20230523.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://usph.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ny20009213x3_ex99-1image01.jpg
<TEXT>
begin 644 ny20009213x3_ex99-1image01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !A ,P# 2(  A$! Q$!_\0
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M$O4!=2PK*JO; H"0#@_-G\?TKD+7XM^,/ ?BQM"\<1QWT$; /-&@60(>CH0
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MBXB?W !^7Z$FN<\2P>.?BT8-(30IO#OA]9!)/-?G$LF.GR\'CL!QG&30!N_
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MA@BMXQ'#&J*.RC%2444L-3I.\5J^KU?WCG6G-6;T[= HHHK<R"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140524120714576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 23, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 23,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">U S PHYSICAL THERAPY INC /NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000885978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0364866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1300 West Sam Houston Parkway South<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">297-7000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">USPH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>ny20009213x3_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="usph-20230523.xsd" xlink:type="simple"/>
    <context id="c20230523to20230523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885978</identifier>
        </entity>
        <period>
            <startDate>2023-05-23</startDate>
            <endDate>2023-05-23</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20230523to20230523"
      id="Fact_c768c2a33e3d4d99b95f597f69bb1f22">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="c20230523to20230523"
      id="Fact_871c3b84f2b44552ae5f2b5e2debfb99">U S PHYSICAL THERAPY INC /NV</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="c20230523to20230523"
      id="Fact_4da354432837412cb84061ac0529e710">0000885978</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20230523to20230523"
      id="Fact_0331098722944fc6b7ab8f11305ee6d6">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20230523to20230523"
      id="Fact_8ff39f9340194391a0afc3c46184ce1d">2023-05-23</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20230523to20230523"
      id="Fact_4cea211ecd234c1a91f72b1a4a0871ea">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20230523to20230523"
      id="Fact_a48b847f433140caae3b5561eb35d24a">1-11151</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20230523to20230523"
      id="Fact_f795340000b44e51aa010c68ece6e5d0">76-0364866</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20230523to20230523"
      id="Fact_a6c72eb342404845bb834c3b41625d8c">1300 West Sam Houston Parkway South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20230523to20230523"
      id="Fact_adb5969ec3d14bb1b18cf6a654955ad0">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20230523to20230523"
      id="Fact_157c26c8257d402abe3d3f84f7ed6568">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20230523to20230523"
      id="Fact_b0c564a36a3a415090ca77fe71b730bf">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20230523to20230523"
      id="Fact_390fb8790fb5430aa8e3ba12ca2aa90a">77042</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20230523to20230523"
      id="Fact_6503c7ae09f84de8be58cd7c02cf9dd2">713</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20230523to20230523"
      id="Fact_91c44c3ced984896b6d7f6633e4f02c2">297-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20230523to20230523"
      id="Fact_dac1bd7f401d4b45acd66ca1167efb49">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20230523to20230523"
      id="Fact_e6c6a7f4e6154cb8892918b952fa2633">USPH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20230523to20230523"
      id="Fact_a82349740eb44d61a74ad7af7c537c0b">NYSE</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="c20230523to20230523"
      id="Fact_09c517c007ec429bb3774ed8efaef097">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20230523to20230523"
      id="Fact_537db99832cd43299b44b8021b7ed653">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20230523to20230523"
      id="Fact_ac262149b87f49d2920f8a932c4b754b">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20230523to20230523"
      id="Fact_5d3f45d64e4948c5864ee065c007dcb4">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20230523to20230523"
      id="Fact_81d73f1718034b8f891540cd76741cae">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
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MYHOA/UY_ 5!+ 0(4 Q0    ( $R+N58'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 3(NY5C )Y^_O
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ 3(NY5IE<G",0!@  G"<  !,              ( !S0$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !,B[E68Q;S.FT$   ]$0
M&               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ 3(NY5I^@&_"Q @  X@P   T              ( !L0P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " !,B[E6EXJ[',     3 @  "P
M        @ &-#P  7W)E;',O+G)E;'-02P$"% ,4    " !,B[E6'#AEZC\!
M   \ @  #P              @ %V$   >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ 3(NY5B0>FZ*M    ^ $  !H              ( !XA$  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 3(NY5F60>9(9 0
MSP,  !,              ( !QQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @  $10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ny20009213x3_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://usph.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName -  ny20009213x3_8k.htm 11</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="ny20009213x3_8k.htm">ny20009213x3_8k.htm</File>
    <File>ny20009213x3_ex1-1.htm</File>
    <File>ny20009213x3_ex5-1.htm</File>
    <File>ny20009213x3_ex99-1.htm</File>
    <File>ny20009213x3_ex99-2.htm</File>
    <File>usph-20230523.xsd</File>
    <File>usph-20230523_lab.xml</File>
    <File>usph-20230523_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ny20009213x3_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ny20009213x3_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "usph-20230523_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "usph-20230523_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "usph-20230523.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "usph",
   "nsuri": "http://usph.com/20230523",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ny20009213x3_8k.htm",
      "contextRef": "c20230523to20230523",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://usph.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ny20009213x3_8k.htm",
      "contextRef": "c20230523to20230523",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://usph.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001140361-23-026687-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-23-026687-xbrl.zip
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M8Y>1=FEU(-C2I,66<T&#O-<4-F17UJMG#-.4P2@,,$K/'(JKTPDRZHB<V>P
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M1;4$#>CXU^;TVRG_UM6)Z):C^59=YOT\\1I]2V":1AHPT9=<IZ7.4P@"4"S
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M3:A4$N.F6M6NKM<>2<'VH/\W:^G(F3)1:@J5"FX<9E'0[RDD0[U1VCR(YC)
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M;896E:<5@[@5CFVC9UUF&J\Q7. TR;3=.+'+XZ'FF'U9E;NPW U!OE!(S.?
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MY=II^PT*S6+8"4:S7'9#^C.%H3B4!5F."&7QQ\+V;/-?Y<Y1,Q..:GS>.$#
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MS'<BW.G 7F$$3]*>>,+@VPX.AA7QH-!$=^;QRY[OE;GIH]F56R9A,YL;[*I
MU<S&XN!H7YA %L8WK7*./,I X0[TD2HF<*<-A7/O8ELSN-#AEH1IK^9+!Z_"
M&EIST6-2;7PI76S&.9R-F<IK7X5]9R:A(1#_Z/,DJCB>B_B $_?*K^<'[77H
M,8\65E=&Y"<H)=<JF+C9I;9!V%$Q(I)#%X;O.3I@KJF;++0Q[EXW-Q'=O$'"
M#0=19BTN08!;-Y5UCZ0Y:YACPG5$3[JK>F%-\53V4U0"[2NU=2@F?]T=^. A
MUZ0P_I+*\I<DW4.3U=PBS"IO,*0OZR]LV$-?BU&L>%HB?*)KB-R=08:4AQE8
MZD?[L?H9\\EQ3EU<[4P=M)$9K]</SX%GG:Q,PV]X:8GTRJ)/:FNT@'!.N6@Z
MX_UN=(.%/3X.6F:Z^] 5M06'<]*!HLP8_. O2+D3"\^?S5XB7$C9.6@8]1#I
M>\V*"+'$UL @%HN&BV1%54UXN6NZ)3?Q'[)NZ/)I4MMAVBD1RUWH,!8M(K*#
MZ[$GC\Y@<(F;7DK?W92;C,EJ-O67)=79/?%N_IV@$U_\_%ELT"&<*/B9AL%
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M/^]5ML .)30"0L2[Y)BF: 4=1,[BU $:J1$JJKL99<=(V@YL;_FZ%^#\5%L
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M>'OY?!5Z8PQ)_(D-/8(53.+4B[IC9-Q/WF#Y%)+2J'9%5T<MGT)@)8Z=<YB
MP5E=^DL^)MZ5-W".<'^#/;_\W0T#QT7X%H1AX W2!Y',:SUNJAY77YNYCZ/'
MU9:HPJW@F/_0P115@@D/65GAUDZZ)[IK>J7KMDJY[M8V\K!*)=K;^+&)8!I/
M-]LK+T"H*S8(K9]702?(5I:D)Z]Y$%GX?\X]4K#?O7G[3N5@.__O.CO;.[N_
MF@);FNJS]+=,3]>9M^QS>CJX.-KG?5 NZ9!S$W7V.#QNWL=@3F 0;1F4#OU<
M=!WIUFC%QRU7)G5?Q4[I BY9JIR!2GV8C%%\G7O)#S,IT_99-].#\V?WS=.5
M:)IN,UCR56<%,9#]7><+F(@(.U&C_L/+5^G+%J/Z]MW378P%&BFU0%6C@&N,
MG0][SCG'C\Y4_*@S9F2Z\ZMQBJDVV#TO\;#M(>^'E;D6'K(K&)CKOI<X[2!)
MGW#I^@+TP8@@]R0CH#"74/^TUB2 M$JUPH^O*->:E2[*YYV^YOBP4__:ZWDV
MH(RS836?E["NZ=1N^J-)OCBUX"Y/AU6-__%7W>D?1SPC-U7=8UVB;QTR:^.9
M1(<]0@)19+C\9,E-I/P2_6C=\E3%L1F''2]6<=9B/!8[=.KPLW6K[@W?I9 T
M4XG6S,4>[<ZU%XY\Y[?MRG;5BN86B*YCV6J$%2 I 9078+(56A M W4,97;@
M,:JVHPB%K,&X+':B3JP+,M0$H'U?Z_.7<=RCKW".G" ?1]@O1+"T%,<@!EO7
M#X99O@=J=VQZXR)-!#_"Z_Z(XIO0[UTB_T_, -=2<-:IO>[(QC6=T%ZF\0K2
MSW5Z(R(;+3=0,$8T,]BVA-4GU*-.&0J6"@$8I%.@]:M"4WVW#9_'@L*D\9UZ
M.<S.<L:U:BX(F(?!L&"QX'CLC@@ K>.'\<WF)#UHR:.8 +.S*P3SH-G 9!+5
MU(-61? ;:.<6]J1+N!N\YN&8P;_4)Y>9BQHAPH*X3N@CQA%FOKB,DN7QN/D;
M_)>Q!B@1A"G 75GUE2K3PS4Y'^:.XL7\6,HPL:YR!8\(Y^@EB5B1^G&*06^"
MU,(&YZ(4DB@*Z&#F?K:WI4(\2XWTHD:S218@VY-@0G@UAH?E(A7!3/%_PJ"B
M2Y^^Q+UC/Y>:1-)> I9WXIN(\>N0W[P^H=AV_QD%5N&,O?0X>]P&"J=-0VH4
M+\0DG;*G,CCE,+[AWM5,'18WT_%)*#;Q=6@)<G-:&!+PFO(JX2"9%M9(!9D1
MJX0\)> LG%.)@.0.&7@Z^DN(1;P1'PR(# ??,4Q[[GD$EJMJEV"Q(H5]@61@
M"$V#X6N=2C7N/%Q]M[MK=ZYV&2$F=Q !/]QX0\4;TK^Z )(G,M" Y@CPIW E
M3 N&=W,5\[S@;^S_Z4[=C03) K.)!W VT;[^9\2]COO$/DEZ%0QS1/R:)Z+B
M-X.B(5.PAQ@H0S#ULRQD[K-;51>WAKAWK-<@S;WT2N\"O1]=@]O*)RS,$:5<
M2"?]E>#^J2RR7IP'OY6.KMP*.G<LF$,C-< B"OPUUPT6;.9N..H)]]L/(<'M
M1Y?>I:"<4(8;/),D?JXYN ) PD5& 71):Y["S")\.-R@!3(3( P&0<;'HLB>
M.($3W.-US^P20@2PI._[O*- &HZ)Y?C.X2CC+0"B5HE#DIJ#3A!YAL?Q=I@U
M1LO<$D:%:0?7Y#C(+3WQF^E1>P7"X9JN3KM)T&&I(R"ZF_BM%D4*KY$&PW*(
M8+/5SD=\00*$H?[Y* :X^SUAOK#X!/& $+J$AZM)8TLEQ:8HSC<4)Y=+1C-1
M!E/<5 *F;/>DN>VSX):4YY9L-I[ZQ(XKD-OB'V<C1W[12GV-&"EXM:"_*D#R
M*1NT;.>;+6EVXR.V 'Z,-Z]#/(403VT=W?D%DAB?Z&XZC3,\XG3W]-PQ*V"Z
MQK 1R 5!_V5[9M*<08 5+>++=9CIA@YSW:W6CI:JI!QL5#=+KV.;]9J0<GEL
M*M!E5#SE*^AXH2=*&.&JP85PG9B4K%6@J=J+(Q\4()#N:89_Z!IYG]4B-7'\
M*,CQ750(&'4&--"=S<(ITM?XOF "\O2#Z#H.:=CVR8DC)4\$/&5W,_^$E*QO
M3,A/?+$V6/M+_"$H*61DBKO$6@7*71+;AA1"@4N!_U)D\/6LG@'5-QI@T3Q1
M/\VHX*_S*CA!Q;_>G.":7NRGA@+&]@-*C*+,2T"2"BB?:%#DVD%075;L>**"
M?(C?Y>FS/-?BW?<U-R"@0OP_7E"/L16W.%M!B_Q".P%]*-_2=D"NVP@VYZMD
MUW4;Y.WZ$!QT0/.$U>[Y'UX%!\YET"<%&O\_?0]_/9&^LNNEMI9ZX;46@YQD
MJY;+K*3;"GL1++Y@-9 !.ACXO8 :Y)(.5G;I1BGHU,0!X2JG2?&9XC(1V3WP
MO4@<&"$9<&3$@TK?">.XYQHB.+A,2>"A(ZX7PWK"*I!UH@U_,"=ZRBA$B3Z
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M,'I@^=('7L^7TQQ/'A^N[\_PJ*DD2^-?+UV-Z;/\JF:YWHU/;S<&/^]@ZTT
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M";'ZM+)C%BF8%U*>?4DE7%,X)E\II16!\NJDB3,*Z!.&\8U:$RY89L+KJN6
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M3S$Q3^/XG5:\AZ6D_E#J&0=PVIN\ZGR%FWUT/[,%OAM@VU3DM47@VY:$_XQ
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MR,HC;$D;9HJ0]IY\1H_7.M&QF,/\Z!'5-.#.))P4-0)%]AA5K:U$]*M,^[5
MRB2G2KGB"0VOD;S6<9+ABX9:&MI&L-0HN,O6E:^@46<&+W%J8?,%Q]HIQ%JD
M,M:YKL /27LZ8ZX,-,QAF8-\N(F2MD0R(4S:Q'E-(EOST[JJX3$9?ZJU#ZD3
MW ![G(AEJ2N(8E_@-"R%$%3Q4N4Y_9_60<&E=1]9J68#B8"EP>L+G9"GOIB4
M_-:FY^(&I(SR0@5[7X^N1N*M=7.J:'8(IPQ,_& 1:= $F0!Z[4=7&[@7XE\K
M#BSV(\CKY>LU(2+7:LY.[9WWYLW%0'PK'65%A>A?*Z\D8*6-"6V[>'VSH>*&
M2K$=PE(,2T"MM('B-LV^&"]O8UNDZ$.!L9CRT=?25 V"DB-C)L@^4WF*')]K
M7R%S-4,G,I@J9B"6F8XSL:2TTSGP8*FKC&W?BN7E'2#:S!EGF]H6SWKMZN;R
MHFU5?9='*I:%XGD9X$*U#GQ9Z]8@,6$P(?$6>"\!081.;)\UV!FM1*&D\:'2
MNSX'*"0XJX.JO:^^+LN<+0W]$H$M""*(1#.6J$<<,Q+G< CUGX>ET3FT6\9Q
MZ#N]\N_M:"W8]NTEDC6VI0X-+<2@@".PU$:5U :KH4ZSEEG'X0DA1 0\4=2D
M_VPJM%PN1U[%H[E=M.0'1<%=9JO4!^*\JLQQ:_W5VOKO%#DZY-F[B\EP/)WB
MWW!Z0-&>8)YP\,>M6X4Y6+K<(IRT5$R/I@<'0[3]R8".1=@5C:ED>#(?K1W\
MLU.?:N4K_TUD4TDCZSW@V<:(>-?^Y@W@9')P(-Y8I. //B>!YPME:JAVB2U+
M:Q,H^1-6'4X.&_U:ZSLUUSH.U:>?4_W-A[)@DD-*?BZ>_+\&2DT$@OJB4\!B
M-%P\,$ISFY(F%"+AB:?.9&"H%-Z"#*(=M2VVORRJB:"NL+QS>0 H7J'@-9(!
M(@=I=(9BZD$;9*Z",'RNUZ#=$Z1->$L%2B[_@!<^T3'K@9>AAFAS.&VPI:D+
MARQMG1,JH?OG<IG65-_:LO8;0(!'GVIX.P5D\8/ %J@@>TI!A._K_;!Z7TCW
M>+#,3^NS\PBLZ&$^=KI;GSUI?WM%5[3 /@1T,IN!GS],$RU&$#C:BQ?[,^)T
M)6)$J%RV"ZMF89QKHV/.GOUQB(X/3:8W7C&TMBM1MT2MJ"Y0\Y0]/,!TU!:<
MKQJ&\^E-3"0BY<I82!"7:D7Y0,"&-8C_$)7%OS1(Z,(F(7)!>.*)I/KNI3:4
M+^29BG['P!V&A!I5.YO;>>B;]Y:S**<R&1%;[4J27U.[ 7_$@2/,H]U 18EN
MEX8Y#S'28 B1S&#_H#]+B4"(O-C;[\S?]G!#E4D;TK@V,D6STZPGJ+I+N-GJ
M#9XL,F C4=JF7[-,#22A*_IR,T "JRP/N9+J/$&F.4)K-G+5AHDLB^CW,@1F
M 0J:0*(^#?=,Y-Q"QXV:L!:[?!-]H':9VY5BF&EUO'] +PLVG3Z@D9BH!3J)
MXAFWT+^T;SA?&"'#*8&,H&?Q;2:X?MP,NJ#Y\"422"UD7LNF%9&#E)M;8PL,
MX=)CXO DXDMA_H^ARBOKEM(EPS>@[N3.FY99^2<'E0?Z'&9Z8EE^3?A\((A4
MSC%E3$(-JYF.T\:6O+&%>)P.[(S8Z'J8O%&A'TTGERV][-&/CD*?Q\0^VUR:
MS/;V>?X#42;PX_2'CCW5&G7O*:(-9QV?R>#0S/UT<-H1F^X"8X!%OLXK[EE-
MZ7.2E2 Y^,_R+0A@S0_:&;:?V,SGVR(C";7;N'79U/F938F;AU^6 HH2'UJD
M]*WAS>00*10CSFS&AT'[/%Q1W'O<7!%L/V83MA_*LL00N/W49T0"VELWAF,4
M;"Y=4/,YW$KW 1@-M/\8((JNW!R%@ /)F1(SDX@EW5-@B@19Z+R+""2:2YXN
M5 BN,+HT%S1T_[1L[U\(F@EOZ.ZN(+JY)A'!B<U,$+;U(VS4LKML:9%;+L ]
M RQQ%T+LO,70G'?3BE.ZB# GAAE&F85VUH1QAR!W.[UZBE!=1-*'L80"CZQV
M)&2AU3+X"-A4%^7ZMF/+*<%?O^H73*_H V73XX(S'M>I&S-Q7',*WPZ&0(7@
M#38CU]SG0#-+??$M]9?F6[!0819)@GTH.?3>D?@WZH%KG>XG-X6M;"U",H'8
M5E1%,5]_UAPK';I!<-?C9HS$*Z(/ZPO/S:*>8Q?'G!7H;I&Z1O1PB@X^.T<;
MR F1^'4+"#\859UJ!H&FT*ZAG'@5_-N66R/MW!C2YEH1$2(GO:+)?#(>_J>[
M?%FA= 4C(@;)6!419.]-^*)@.NA-U*TKFF&9A:G(U72'.ST*%PLA(1%M\E<7
M\@T;?1UY&B:1TV#^#C[)5\TV$QS'G(V*E__8HS_,C\3[7_40;8;C^8H2"ZGY
M%\Q?M^N&+SFD;YM'PM-$<^<9%!A1&U%E1:MH^-5H4ZT',"9C(AF0BI3-H2<9
M$+X('56V]*\N62SG_F,:;Q<5X*:?EUU[8&[D>0;FM%QJCRE9W=.P4:W[LYH_
M\H<=T[_L#SO6;*7]=+I+?Z/#'YJ_1/H?4$L#!!0    ( $R+N58]ZIZ10@,
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M.%<DSEA\&)0$*%>@3')8P&OL*GG)^LO FW,$^%6NG1? 19)L,*U=!D8Y7 R
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M;E.7 :HHD_S'*.#B6PLZ1?KC)$IXR)V_$OGBD^TMFS!Z3P[/W5C5MT!-%JA
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M2P$"% ,4    " !,B[E6[FD6BIH6  ":E   $P              @ $
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M2P$"% ,4    " !,B[E6V(0E#9@+  "2)   %P              @ %)R
M;GDR,# P.3(Q,W@S7V5X.3DM,BYH=&U02P$"% ,4    " !,B[E6/>J>D4(#
M   M#P  $0              @ $6U   =7-P:"TR,#(S,#4R,RYX<V102P$"
M% ,4    " !,B[E6-2?!GW\(  !T6   %0              @ &'UP  =7-P
M:"TR,#(S,#4R,U]L86(N>&UL4$L! A0#%     @ 3(NY5CU)4$K9!0  Z3X
M !4              ( !.>   '5S<&@M,C R,S U,C-?<')E+GAM;%!+!08
1    "  ( !@"  !%Y@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
